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Abstract  
Friedreich‟s Ataxia (FRDA) is a neurodegenerative disorder caused by a deficiency of the protein 
frataxin and characterized by oxidative stress. The first aim of my research project was to analyze 
the effects of tocotrienol in FRDA patients. Patients received for 2 months a low dose of 
tocotrienol. A number of biochemical parameters related to oxidative stress were studied. We 
consistently showed that taking for 2 months a low dose of tocotrienol led to the decrease of 
oxidative stress indexes in FRDA patients. Also, this study provides a suitable model to investigate 
the efficacy of natural compounds to counteract the oxidative stress in FRDA.  
Furthermore, we investigated whether the tocotrienol was able to modulate the expression of the 
frataxin isoforms (FXN-1, FXN -2, FXN-3) in FRDA patients. We demonstrated that tocotrienol 
leads to a specific and significant increase of FXN-3 expression. As no structural and functional 
details were available for FNX-2 and FXN-3, 3D-models were built. FXN-1, the canonical isoform, 
was then docked on the human iron-sulphur complex and functional interactions were computed; 
when FXN-1 was replaced by FXN-2 or FNX-3, we found that the interactions were maintained, 
thus suggesting a possible biological role for both isoforms. 
The second aim of my research project was to investigate the role of a single nucleotide 
polymorphism (SNP) in the protein Sirtuin 6 in FRDA patients. In fact, it was known that those 
who harbour a SNP (Asn46/Ser46) in the gene enconding Sirt6 show a better outcome those 
individuals who are homozygous for the Asn 46 allele. We found that fibroblasts and iPSC-derived 
neurons from FRDA patients harboring the SNP (Asn46/Ser46) have a reduced amount of Sirt6 
protein compared to cells from individuals who are homozygous for the prevalent Asn allele. Our 
studies provide new information on the role of Sirtuins in FRDA pathogenesis.  
 
 
 
 
  
Index 
 
Chapter I 
1.1 Introduction to Friedreich‟s Ataxia (FRDA) ............................................................................................ 1 
1.2 Clinical Features of Friedreich‟s Ataxia ................................................................................................... 3 
1.3 Etiopathogenesis of Friedreich‟s Ataxia ................................................................................................... 7 
1.4 Epigenetic Mechanisms in Friedreich‟s Ataxia ...................................................................................... 13 
1.5 Structure and Function of the Frataxin Protein ....................................................................................... 15 
1.6 Pharmacological Treatments and Therapeutic Strategies for Friedreich‟s Ataxia .................................. 20 
 
Chapter II  
Oxidative Stress 
2.1 Radical Oxygen Species (ROS) .............................................................................................................. 30 
2.2 Physiological and Pathological Functions of ROS ................................................................................. 32 
2.3 Cellular Antioxidant Systems ................................................................................................................. 37 
2.4 Oxidative Stress and Biomarkers of Oxidative Stress ............................................................................ 44 
2.5 Role of Oxidative Stress in Friedreich‟s Ataxia ..................................................................................... 47 
 
Chapter III 
Research Project 
Part I: Aims .................................................................................................................................................... 50 
Part II: Aims ................................................................................................................................................... 51 
 
Chapter IV: Role of Oxidative Stress in the Freidreich‟s Ataxia 
Materials and Methods Part I ......................................................................................................................... 53 
Supplementary materials Part I ...................................................................................................................... 61 
Results Part I ................................................................................................................................................. 64 
Discussion and Conclusions Part I ................................................................................................................ 77 
 
Chapter V: Generation of human induced Pluripotent Stem Cells (hiPSCs) from Friedreich‟s Ataxia 
(FRDA) patients 
Materials and Methods Part II ........................................................................................................................ 81 
Supplementary materials Part II ..................................................................................................................... 86 
Results Part II ................................................................................................................................................ 88 
Discussion and Conclusions Part II ............................................................................................................ 105 
 
References…………………………………………………………………………………………………107 
 1 
Chapter I 
 
1.1 Introduction to Friedreich’s Ataxia (FRDA) 
Friedreich‟s Ataxia (FRDA, OMIM #229300) is a progressive neurodegenerative disorder; it was 
described for the first time by the German physician Nikolaus Friedreich (1863). It is the most 
frequent inherited autosomal recessive ataxia with a prevalence of 1:50,000 in Caucasian 
populations, while it is rare in sub-Saharan African populations and is very rare in the Far East 
(Vankan. 2013). FRDA is characterized by a progressive degeneration of the central and peripheral 
nervous system and is also associated to cardiac hypertrophic myopathy and diabetes mellitus. The 
cardiomyopathy and the subsequent cardiac failure are the common cause of death in FRDA 
patients. The first symptoms that occur during the puberty include gait instability, dysarthria, 
areflexia, sensory loss and pyramidal signs (Santos et al., 2010). In the majority of cases, FRDA is 
caused by a (GAA)n trinucleotide repeat expansion in the first intron of FXN gene (Frataxin 
encoding gene) located on chromosome 9q13, that encodes the protein Frataxin (Campuzano et al., 
1996). A small percent of patients are heterozygous, with point mutations found on the other allele. 
The (GAA)n repeats cause a epigenetic silencing of FXN gene and consequently a decreased of 
levels of FXN mRNA. In FRDA patients, the levels of FXN mRNA are around 4-25%, whereas in 
the asymptomatic carriers FXN mRNA levels are about 50% with respect to the normal subjects. It 
has been suggested that the mechanism responsible for the silencing of the FXN gene is due to the 
ability of the expanded triplets to adopt an alternative DNA structure GAA-TTC-GAA. This 
unusual conformation would be able to hamper the process of FXN mRNA transcription, with 
consequent reduction of the quantity of the transcript. Additionally, (GAA)n repeats can induce the 
heterochromatinization of the FXN gene, which can contribute to gene silencing (Ohshima et al., 
1998).  
Frataxin is a mitochondrial protein involved in the regulation of mitochondrial iron homeostasis, in 
the biosyntesis and assembly of iron-sulfur (Fe-S) clusters and is involved in, nuclear damage and 
chromosomal instability (Karthikeyan et al.,2002). Deficiency of frataxin cause the imbalance of 
iron homeostasis, increased oxygen radical production and a major hypersensitivity to oxidative 
stress (Rustin et al.,2011).  
There is no approved treatment for FRDA. Current drug screening studies are focused on 
ameliorating neuronal cardiac iron accumulation using iron chelators and enhancing respiratory 
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chain function using idebenone, a synthetic analog of coenzyme Q10 and/or reducing oxidative 
damage with antioxidant compounds. Alternative therapeutic approaches are based on molecules 
able to revert the silencing of FXN gene and restore the frataxin expression: To this purpose, 
chromatin-modifying molecules such as histone deacetylase inhibitors (HDACi) and compounds 
that increase the level of frataxin protein with neuroprotective and cardioprotective activities, such 
as the recombinant human erythropoietin (rHuEPO) are being currently tested. The effectiveness of 
these treatments in improving cardiac and neurological outcomes in Friedreich ataxia patients is 
under evaluation. 
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1.2 Clinical Features of Friedreich’s Ataxia  
The Quebec Collaborative Group in 1976 and Harding in 1981 have defined the essential clinical 
criteria for the diagnosis of FRDA (Fig.1.1). Additionally, with the application of molecular genetic 
methods, it has become possible to perform also the molecular diagnosis of atypical phenotypes 
FRDA. Currently, there are no valid outcome markers to monitor the progression of the disease. 
Therefore, the following clinical scales are applied to the assessment of disease severity and 
progression in FRDA: The International Cooperative Ataxia Rating Scale (ICARS), the Friedreich‟s 
Ataxia Rating Scale (FARS) and the Scale for the Assessment and Rating of Ataxia (SARA) (Bϋrk 
et al., 2013). 
 
-The International Cooperative Ataxia Rating Scale (ICARS) has been validated for use in patients 
with focal cerebellar lesions and was tested for acceptability, reliability and validity in FRDA. The 
ICARS scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, 
limb ataxia, dysarthria, and oculomotor disorders.  
 
-The Friedreich‟s Ataxia Rating Scale (FARS) has been validated specifically for neurological 
features of FRDA. It is based on a neurological examination of bulbar, upper limb, lower limb, 
peripheral nerve, and upright stability/gait functions. Further, functional staging and activities of 
daily living (ADL) assessment are incorporated. The scales are supplemented by quantitative 
performance measures including 8 m walk at maximum speed (8MW), the 9-hole peg test (9HPT), 
PATA rate (number of repetitions of the bisyllabic phrase „PATA‟ within 10 s) and low-contrast 
letter acuity.  
 
-The Scale for the Assessment and Rating of Ataxia (SARA) is a clinical scale restricted to 
cerebellar clinical symptoms and does not take into account any extracerebellar features. The eight 
measuring items are related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast 
alternating movements and heel-shin test. A maximum score of 40 reflects most severe ataxia.  
 
All scales measure motor aspects of cerebellar dysfunction including ataxia of stance, gait and 
limbs. SARA being the shortest scale, FARS and ICARS also covering further aspects of the 
neurological examination (e.i. dysarthria or oculomotor symptoms). Only FARS considers features 
not directly related to the physical examination, such as activities of daily living ( Bϋrk et al; 2013). 
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Based on the clinical features, FRDA is classified into two phenotypes, classical and atypical. In the 
classical phenotype of FRDA, at the onset around puberty neurological and non neurological 
features arise. The neurological features are gait and limb ataxia, areflexia and dysarthia. The ataxia 
is of mixed origin and is caused by cerebellar degeneration, peripheral sensory neuropathy, 
cerebellar and vestibular pathology (Delatycki and Corben 2012). The first pathological changes 
occur in the dorsal root ganglia (DRGs) with thinning of dorsal roots (DR), loss of large sensory 
neurons associated with neurodegeneration in Clark‟s and posterior columns, pyramidal signs and 
spinocerebellar tracts of spinal cord (Puccio et al., 2000). Neuropathological examinations have 
confirmed overall reduction in the size of DRG, atrophy or active destruction of nerve cells, 
„„residual nodules‟‟ (also known as nodules of Nageotte) and gray discoloration of the thinned DR 
(Koeppen et al., 2009). Gait and limb ataxia causes increasing difficulties in daily activity, walking, 
washing and dressing. Pyramidal weakeness and areflexia are prominent in the lower limbs (LLs) 
compared to the upper limbs (ULs) in the early stage associated with a reduction of muscle tone, 
cramps and spasms (Delatycki et al; 2012). Moreover, dysarthria characterized by consonant 
imprecision, decreased pitch variation and reduced phrase length is frequent as early sign in more 
than 90% of patients. In the early stage of disease the ophthalmic system with fixation instability, 
square wave jerks and nystagamus is also involved. Hearing difficulties caused by auditory 
neuropathy are a common and understated problem, which can be socially very disabling even in 
the early stages of disease. Almost, all patients show disordered neural conduction in the central 
auditory pathways which functionally results in impaired speech understanding in conditions of 
background noise typical of everyday listening conditions, which can lead patients to be able to 
access only 50% of information available, compared to unaffected individuals (Rance et al. 2010). 
Non neurological manifestations such as cardiomyopathy, diabetes and skeletal abnormalities are 
common in FRDA classical phenotypes. The hypertrophic and progressive cardiomyopathy is a 
common cause of death in FRDA patients. The cardiac symptoms occur early during the first or 
second decade of life, but the clinical signs of cardiac involvement develop only later in the course 
of the disease and include palpitations and uncontrolled arrhythmias. The echocardiographic 
hallmark of Friedreich‟s cardiomyopathy is left ventricle (LV) hypertrophy to which it may be 
added that of the posterior wall and of septa. The histological changes in the LV mainly consist of 
cellular hypertrophy, diffuse fibrosis, and focal myocardial necrosis. In most FRDA patients, the 
QRS duration is normal. Electrocardiographic signs of LV cardiomyopathy which arise during the 
advanced stages are high S-wave in V1 and V2, and high R-wave in V5 and V6 and T-wave 
abnormalities (i.e., inversion or flattening) (Weidemann et al. 2012). 
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Approximately 10-20 % of FRDA patients develop diabetes mellitus and about 24%- 50% have 
intolerance to carbohydrates. The pathogenetic mechanism of diabetes is complex and includes both 
a dysfunction of pancreatic β islands and peripheral insulin resistance similar to that at the base of 
other mitochondrial disorders (Santos et al. 2010). Data derived from a study performed in FRDA 
patients, suggested that diabetes in FRDA is caused by loss of islet cells similar to common Type 1 
diabetes, but without HLA-association and without serologic evidence for autoimmune destruction 
of the islet cells (Schonele et al., 1989). The diabetes onset is often acute and the FRDA patients 
require insulin administration. In a number of cases, the first presentation of diabetes was 
ketoacidosis, which may be fulminant. (Cnop et al; 2012). Other non-neurological complications 
arising in FRDA patients affect the skeletal system, particularly scoliosis and foot deformities with 
pes cavus and talipes equinovarus.  
In addition to classic FRDA phenotypes, atypical variants have been described. They include the 
Acadian type, late-onset FRDA (LOFA), very late-onset FRDA (VLOFA) and FRDA with retained 
reflexes (FARR). In atypical variants of FRDA, neurological manifestations typical of the classical 
phenotype remain frequent, which gait and limb ataxia, dysarthia and pyramidal involvement. 
However, the non neurological clinical complications (cardiomyopathy, diabetes and skeletal 
deformities) are less frequent or absent. Finally, in literature few cases of early-onset FRDA, have 
been descroibed; they display an atypical and more severe phenotype characterized by onset before 
age of 5, associated with faster progression of disability, frequent cardiomyopathy and skeletal 
complications.  
 
 
 
Fig. 1.1 Clinical Features of Friedreich’s ataxia. 
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Fig.1.2 Schematic drawing of axonal pathology in peripheral and 
central nervous systems. 
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1.3 Etiopathogenesis of Friedreich’s Ataxia 
 
Genetic Mechanisms 
 
As already mentioned in the introduction, the majority of FRDA cases are caused by a (GAA)n 
trinucleotide repeat expansion in the first intron of FXN. The human FXN gene was identified in 
1996 by Campuzano; it is localized on the chromosome 9q13. The genomic region containing the 
FRDA locus was analyzed using new polymorphic microsatellite markers. The only gene within the 
minimum candidate region was X25 (subsequently named FRDA and now FXN) and the FRDA 
locus was at last identified. Two studies showed evidence of genetic heterogeneity in FRDA. 
Occasional reports appearing in literature describe patients who present FRDA clinical symptoms, 
but in whom a mutation in the FXN gene cannot be detected. Thus, a second locus FRDA2, mapping 
to chromosome 9p23-p11, was proposed (Christodoulou et al., 2001), but no subsequent studies 
have confirmed these observations. 
FXN gene is composed of seven exon (1-4, 5a, 5b and 6); exon 6 is not transcribed. The main 
messenger RNA is composed of five exons and encodes the protein frataxin (isoform FXN 1 of 
7168bp). There are also two other transcripts with different lengths that are denominated isoform 2 
(FXN2) and 3 (FXN 3), the formation of which is due to alternative splicing. Comparing the 1 and 
2 isoform, it is possible to note that the variation of splicing is between exon 4 and 5a; this causes 
an increase of nucleotides at the end of the fourth exon in the second isoform FXN-2 (7176bp). In 
the third isoform, FXN-3 (980bp), mRNA alternative splicing produces a transcript identical to 
isoform 1 until the end of the fourth exon, then there is a skip in the transcript that causes the 
deletion of exon 5a but includes exon 5b (Figure 1.3). Isofom 3 is produced at lower levels than 
isoforms 1 and 2. No functional data about the protein isoforms have been reported. FXN gene 
expression and production of the protein frataxin are ubiquitous and have an essential role 
especially during the early stages of embryonic development. Studies of mouse FXN expression 
homologue during embryonic development by Northern blot analysis and RNA in situ hybridization 
confirmed that the FXN expression is not detectable at E8.5, is weak at E12.5, then increases until 
E16.5, when no further change is observed until the neonatal period. At E14.5, the expression is 
high in the ventricular zone of the brain, the anterior horns of the spinal cord, the large neuronal 
cells in the DRG and in the granular layer of the cerebellum (Jiralerspong et al., 1997). The levels 
of FXN mRNA and protein show tissue specificity that partially correlates with the main sites 
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affected by the disease. In humans, adults show the highest levels of expression in the heart and 
spinal cord, with intermediate levels observed in the cerebellum, liver, skeletal muscle, and 
pancreas and very low levels in the cerebral cortex. Furthermore, FXN mRNA is found in non-
neural tissues as kidney and brown fat (Campuzano et al., 1996 and Pianese et al al.,2002). 
Recently, Xia and co-workers (2012) have identified two novel isoforms of frataxin specifically 
expressed in affected cerebellum and heart. The transcripts were alternately spliced using exons 
1a/1b and generated either an exon 1a-containing transcript encoding a 164 amino acid protein 
(isoform III), or an exon 1b-containing transcript encoding a protein of 135 amino acids (isoform 
II). b. Exons 2-5a are present in all three frataxin isoforms (Xia et al., 2012). Frataxin isoforms II 
and III were expressed as transcripts and proteins in the cerebellum and heart of individuals with 
FRDA, respectively. Importantly, both isoforms could facilitate iron-sulfur cluster assembly in vitro 
(Xia et al., 2012). Additional FXN transcripts have also been identified; however, their 
physiological relevance remains unclear (Pianese et al., 2004; Xia et al., 2012). 
 
 
Fig.1.3 Structure of human FXN gene 
 
 
The promoter region of the human FXN gene consists of 1,255 bp and bears different repetitive 
elements. They include L2 (LINE) and Alu (SINE) elements as well as Mammalian-wide 
Interspersed Repeats (MIRb) and mariner DNA transposons (Greene et al., 2007). In addition, in the 
first intron of the gene an E-box element that modulates the activity of the promoter is present, in 
fact, its deletion leads to a significant reduction in the detection of a reporter (Cossès et al., 2000). 
The regulation of human gene FXN is very little known, although it is known that the sequence E-
box is able to bind transcription factors belonging to the family of proteins basic helix- loop-helix 
(bHLH). A protein that could bind to this sequence is the factor muscle-specific Mt, however its 
biological importance is not clear (Greene et al., 2007). Many reports have recently shown that the 
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expression of frataxin is regulated by iron. The addition of the iron chelator deferoxamine in the 
culture medium of fibroblasts and lymphoblasts of patients with FRDA leads to a reduction of the 
level of frataxin both as mRNA and protein amounts. Studies based on the use of promoter-
luciferase constructs have shown that the iron acts as a transcriptional regulator, but the mechanism 
remains to be clarified (Li et al., 2008). Moreover, other authors have demonstrated that the murine 
gene FXN seems to be directly regulated by the transcription factor HIF-2α (Hypoxia-Inducible 
Factor 2α, encoded by the gene EPAS1). The levels of frataxin, both mRNA and protein, are 
reduced by 50% in the liver of Knock-out Epas-/- mice compared to control. However, it is not 
known whether the human gene FXN is also regulated by HIF-2α. (Oktay et al., 2007). Finally, two 
new regulatory factors influencing the frataxin expression, TFAP2 and SRF were identified. TFAP2 
(activating enhancer binding protein AP2) is a developmentally-regulated, retinoic-acid inducible 
transcriptional activator, which directly binds to the promoter region of the FXN gene. Also, the 
expression of TFPAP2 is significantly down-regulated in HEK293 and SH-SY5Y cells in an iron-
dependent manner, suggesting that iron may in turn alter the levels of FNX mRNA expression by 
FFAP2 regulation. SRF (c-fos serum response factor) is a ubiquitously expressed factor able to 
influence, in a cell-line specific way, the FXN mRNA levels (Li et al., 2010). Finally, low levels of 
FXN expression were also found in association with the depletion of PGC1a, the co-activator of 
peroxisome proliferator-activated receptor gamma 1-αlpha (PPARGC1A) (Coppola et al. 2009; 
Marmolino et al. 2010). 
 
 
Fig.1.4. Regulatory component of human FXN gene. 
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Molecular Mechanisms 
 
Most FRDA patients (about 96%) are homozygous for (GAA)n trinucleotide repeat expansions and 
the remaning 4% of cases are compound eterozygous for a (GAA)n expansions and point mutations 
in the coding region of gene. The (GAA)n repeats derive from an expansion of poly (A) sequence 
A5TACA6 placed in the center of the element AluSx, flanked by a repeat of 13 bp 
(AAAATGGATTTCC) (Campuzano et al., 1996).  
The expansion of (GAA)n repeats arises from inter-generational instability in the germinal maternal 
line (oocyte) through expansion and/or contraction events, whereas the alleles transmitted by the 
father (sperm) undergo only contraction (Delatycky et al., 1998 and De Michele et al., 2000). 
Moreover, a trend of increase of (GAA)n expansions has been demonstrated to occur via somatic 
mitosis. This instability is age-dependent, and is most common in certain individual cells, such as 
pseudo-unipolar neurons of the dorsal root ganglia (De Biase et al., 2007). It is suggested that errant 
DNA mismatch repair may be a common denominator amongst the array of alterations caused by 
DNA repeat expansion. Recently, it has been shown that MSH2, MSH3 and MSH6 enzymes of 
mismatch repair (MMR enzymes), are highly expressed in induced pluripotent stem cells (hiPSCs) 
derived from FRDA patients cells compared with fibroblasts and neuronal stem cells (Ku et al., 
2010 and Du et al., 2012). Moreover, in a cellular model of instability-related repeats, the 
knockdown of the mismatch repair proteins, MSH2 and MSH3 slows down the GAA•TTC 
expansion (Grabczyk et al., 2012). Expanded (GAA)n repeats (67-1700 bp) were associated with 
decreased levels of FXN mRNA (4-29% of normal in FRDA, ~50% of normal in asymptomatic 
carriers). The length of (GAA)n trinucleotide repeats correlates positively with the disease severity 
and correlates negatively with the age of onset. Several studies have described a relation between 
the size of the GAA repeat expansion and the presence and timing of several features of the disease. 
The GAA•TTC expansion in FXN does not alter the protein sequence. Although, the precise 
mechanism remains unclear, there is substantial evidence that the expanded (GAA)n repeats do not 
affect the RNA splicing of the FXN gene but occur during the transcription process (Campuzano et 
al., 1996). 
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Fig.1.5. GAA repeat expansion in FXN gene (Grabczyk) 
 
 
Currently it has been proposed that the mechanism responsible for the silencing of the gene FXN 
can be attributed to two models; 1) formation of non-B-DNA structure and 2) formation of hybrid 
DNA-RNA non coding (Figure 1.6.) duplexes. In both cases, heterocromatin formation occurs 
(Figure 1.7). 
These secondary structures include purine:purine:pyrimidine and pyrimidine:purine:pyrimidine 
triplexes, which may down regulate FXN expression through a physical blockage effect on 
transcription by making it more difficult for the transcription RNAPII complex to unwind the DNA 
template and move forward (Sakamoto et al., 2001). In addition, tryplex structures known as “sticky 
DNA” are formed by unusual hydrogen bonds between G•G, G•A or A•A. (Kumari and Usdin 
2012). Furthermore, triplex structures formed by (GAA)n repeats allow the formation of stable 
RNA•DNA hybrids (R-loops) during the transcription (LeProust et al. 2000). Triplex structures 
inhabited by expanded (GAA)n repeats were shown to be recognized by the DNA repair machinery 
in various models including hiPSCs derived from FRDA patients (Ku et al. 2010 and Du et al. 
2012).  
In addition to these alternative structures of DNA characteristic of the FXN gene, the repeated 
sequences of triplets can induce a packaging of the genomic regions involved in inaccessible 
heterochromatin, further contributing to FXN genic silencing.  
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Fig. 1.6 Examples of different structures formed by GAA•TTC repeats 
 
 
 
 
 
Fig.1.7 A hypothetical model for the heterochromatinization of FXN gene 
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1.4 Epigenetic Mechanisms in Friedreich’s Ataxia 
There are different neurological disorders caused by triplet expansions such as myotonic dystrophy, 
spinal muscular atrophy, and fragile X syndrome, in which epigenetic modifications play a pivotal 
role in the pathogenesis of these diseases. Numerous studies have confirmed that the silencing of 
FXN gene mediated by (GAA)n repeats expansions is originated by epigenetic changes, as the 
direct methylation of DNA, histone modifications and alternative mechanism of transcription in 
antisense direction. FXN gene contains a CpG island covering the promotor, the first exon and the 
beginning of the first intron. Bisulfite mapping demonstrates that the regions adjacent to the repeats 
in intron 1 of FXN gene are methylated in both unaffected and affected individuals. However, an 
increase in the number of methylated residues has been reported in FRDA cells (Green et al., 2007). 
Also, autopsy of patients arise the elevated levels of CpG methylation upstream of (GAA)n (Al-
Mahdawi et al., 2008). Moreover, elevated levels of CpG methylation upstream of (GAA)n have 
been observed in autoptic tissues from FRDA patients (Mahdaw et al., 2008). Finally, two large 
scale studies on peripheral blood mononuclear cells also confirmed that higher degree of DNA 
methylation was proportional to the length of (GAA)n and positively correlated to FXN gene 
silencing and to disease severity (Castaldo et al., 2008). In addition, the acetylation status of 
histones and other proteins involved in transcription regulation is crucial for the regulation of gene 
expression. Heterochromatin is characterized by histone hypoacetylation, histone H3 lysine 9 and 
lysine 27 methylation, and the association of histone deacetylase enzymes, specific histone 
methyltransferases and heterochromatin proteins such as members of the Heterochromatin Protein 
(HP1 family) and Polycomb group proteins. The first report in support of an epigenetic silencing 
mechanism in FRDA came from Festenstein and colleagues (2006), who showed that a transgene 
containing GAA•TTC repeats was silenced in vivo, in a manner reminiscent of the position-effect 
variegated gene silencing. In this study, repeat-induced silencing was augmented by over-
expression of the heterochromatin protein HP1, and the silenced transgene was packaged into 
condensed chromatin, as evidenced by resistance to nuclease digestion (Saveliev et al. 2003). In 
addition, it has been shown that the alleles of FRDA patients are enriched with a variety of histone 
modifications characteristic of silenced genes, including hypoacetylated H3 and H4 and 
dimethylation and trimethylation of histone H3 lysine 9 (H3K9). Herman and co-workers (2006) 
have shown for the first time that H3K9 methylation, which is typical of heterochromatin, is present 
at the FXN locus in primary lymphocytes and in lymphoblastoid cell lines from individuals with 
Friedreich‟s ataxia. Furthermore, they have shown that it is possible to reverse the aberrant 
 14 
silencing of FXN using a new HDAC inhibitor. A similar pattern of epigenetic changes has also 
been found in the affected tissues (brain and heart) from mouse models of the disease and in 
Friedreich‟s ataxia autopsy-derived brain, cerebellum, and heart (Al-Mahdawi et al. 2008 and Rai et 
al. 2008). Results obtained from ChIP data reporting the histone modifications on the FXN locus 
have confirmed high levels of heterochromatin marks in the first intron of the FXN gene (Saveliev 
et al., 2003). Furthermore, ChiP DNA analysis using primers specific to the (GAA)n has revealed 
that the classical heterochromatin marks histone H3 lysine 9 dimethylation (H3K9me2), histone H3 
lysine 9 tri-methylation (H3K9me3) and histone H3 lysine 27 tri-methylation (H3K27me3) are 
enriched particularly in the immediate flanking regions of expanded (GAA)n repeats, whereas 
acetylation marks were reduced (Green et al., 2007, Al-Mahdawi et al., 2008, Castaldo et al., 2008 
and Soragni et al., 2008). This suggests that heterochromatin is bidirectionally spreading from the 
expanded (GAA)n tract within the FXN locus (Chan et al., 2013). Important is also the discovery by 
De Biase and co-workers of a CTCF binding site 154bp downstream of TSS1 within the 5′UTR of 
the FXN gene. CTCF (a zinc finger protein) is a chromatin insulator protein known to prevent the 
spreading of heterochromatin, that results to be depleted in FRDA patient fibroblasts; its depletion 
is associated with increased antisense transcription (De Biase et al. 2009). Finally, FXN silencing 
may be due to a mechanism of reverse transcription via the activity of the RNA-interference 
complex. An FXN antisense transcript called “FXN antisense transcript 1” (FAST1) has been 
identified, which seems to be produced at higher levels in the fibroblasts derived from FRDA 
patients. 
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Fig.1.8. A epigenetic model for FRDA 
1.5 Structure and Function of the Frataxin Protein 
Structure of frataxin  
Frataxin is a small acidic protein (with isoelectric point around pH 4.9). It is highly conserved in 
most organisms from bacteria to mammalians (Gibson et al. 1996 and Adinolfi et al. 2002). A 
frataxin homolog was also identified in the human parasite Trichomonas vaginalis (Dolezal et al. 
2007). Due to its small size, it was possible to solve the structure of frataxin by Nuclear Magnetic 
Resonance analysis (NMR). The structure of the human frataxin was determined both in solution 
and in crystalline form (Musco et al., 2000 and Dhe Paganon 2000) as well as that of its 
homologues CyaY in E. coli (Noir et al., 2004 and Cho 2000) and Yfh1 in the yeast Saccharomyces 
cerevisiae (He et al., 2004 and Kalberg et al., 2006). Frataxin is characterized by a flat 𝛽-sheet 
platform supported by two parallel 𝛼-helices at N and C terminus. Frataxin protein contains two 
structural elements that are conserved in all frataxin orthologs: (i) the presence of acidic residues in 
the first 𝛼-helix (𝛼-1) and 𝛽- strand (𝛽-1) which form a negatively charged surface; (ii) a neutral flat 
area on the 𝛽-sheet surface that probably allows the interaction of protein partners on frataxin 
(Sirano et al., 2000). 
An N-terminal block of 81–92 residues, completely absent in prokaryotes and poorly conserved 
among eukaryotes, is unfolded and highly flexible (Huynen et al., 2001). The conserved C-terminal 
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domain fold in a mixed αβ structure that consists of two helices packing against a contiguous anti-
parallel beta-sheet assembled in the sequence alpha-(beta) 5–7-alpha of the protein and comprises a 
highly conserved block of ca. 100–120 amino-acids. Frataxin is a nuclearly encoded protein, 
expressed in the cytoplasm and imported in the mitochondrion through an import signal 
(mitochondrial targeting sequence; MTS) contained in the N-terminus. The MTS sequence is 
removed by proteolytic cleavage in two steps, to produce the mature protein (Branda et al., 1999 
and Cavadini et al., 2000). The maturation of human frataxin, as well as that of yeast, depends on 
the MPPs (mitochondrial processing peptidases). Using an YTH (yeast two-hybrid) assay, it was 
shown that the N-terminus of murine frataxin interacts with the β subunit of the MPP (Koutnikova 
et al., 1998). These enzymes cut the first precursor of frataxin to produce an intermediate form, 
which will then be converted into the mature frataxin. 
 
 
 
Fig1.9. Structure-based sequence alignment of human frataxin with homologues from prokaryotes and 
other eukaryotes 
 
Fig.1.10 Structure of frataxin 
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Fig.1.11. Iron binding of frataxin 
 
In yeast frataxin ortholog Yfh1, the first mitochondrial processing peptidase (MPP) cleavage site 
lies between residues Y20 and M21 (RRY ↓ MIA), while the second cut is made between residues 
F51 and V52 (KRF ↓ ESR). Detailed analysis of the two sequences, residues 1-20 (domain I) and 
21-51 (Domain II), have established that the domain I is the matrix- targeting signal (MTS). 
Furthermore, it was observed that in the absence of domain II, the MTS is unable to mediate 
transport of frataxin in mitochondria (Gordon et al., 2001). Maturation of pre-Yfh1 protein requires 
also the sequential action of Ssc1 and Ssq1, mitochondrial chaperones members of the Hsp70 
family (Knight et al., 1998 and Voisine et al., 2000). Finally, Tim4 plays a pivotal role in importing 
into the mitochondrial inner membrane and is required for the binding of Ssc1 to Yfh1 (Geissler 
2000). 
Human frataxin is synthesized as a precursor of 210 amino acids imported to the mitochondrion, 
and undergoes maturation by the MMP through a two-step process that leads to the successive 
generation of an intermediate form of 19 kDa cleaved between G41 and L42 (residues 42–210) and 
a mature form of 14 kDa (residues 81–210) (Koutnikova et al. 1998; Condò et al. 2007 and 
Schmucker et al. 2008). Another form starting at S56 was also reported (Cavadini et al., 2000), but 
it is now widely accepted that the 81–210 form is the most abundant species, both in normal 
individuals and in FRDA patients (Condò et al. 2007; Schmucker et al. 2008; Gakh et al. 2010).  
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Function of Frataxin  
Frataxins are essential proteins whose deficiency causes a range of metabolic disturbances such as 
oxidative stress, deficit of iron-sulphur clusters, and defects in heme synthesis, energy metabolism, 
stress responses, and mitochondrial dysfunction. Numerous studies, also confirmed the role of 
frataxin in physiological and pathological processes such as embryonic development, cellular 
differentiation, cancer and regulation of antioxidant defense (Santos et al., 2009). Although, the 
precise function of frataxin remains to this day unknown, it is clear that frataxin is involved in the 
cellular iron homeostasis. The first hypothesis about the role of frataxin derives from studies in 
yeast (S cerevisiae), in which it was observed that deletion of frataxin ortholog (Δyfh1) gene results 
in a reduced cellular respiration, high sensitivity to hydrogen peroxide and copper, low levels of 
cytosolic iron and a constitutive activation of the system of iron transport in the plasma membrane. 
Also, in the yeast Δyfh1 mutant, deletion of frataxin homolog 1 (YFH1) produces a 10-fold increase 
in mitochondrial iron and increased sensitivity to oxidants (Babcock et al., 1997 and Foury et al., 
1997) These data suggested a role of frataxin in mitochondrial iron homeostasis, and a role of 
frataxin as a mitochondrial iron chaperon was proposed. Iron is a well-known catalyst of free 
radicals, and excess iron in mitochondria most probably explains the increased sensitivity to 
hydrogen peroxide and oxidative stress. Subsequent works with mice completely deficient in 
frataxin demonstrated cardiac degeneration and iron accumulation (Cosseè et al., 2000). Further, in 
human FRDA patients, excess iron is observed in hearts, liver, pancreas and neural tissue (Bradley 
et al., 2000 and Lamarche 1980). Indeed, it was suggest that the iron accumulated in mitochondria 
of FRDA patients causes their hypersensitivity to oxidative stress, as a consequence of Fenton 
Reaction (Fe
2+
 catalysed production of hydroxyl radicals). A second hypothesis for frataxin 
function is its role in the biogenesis of iron–sulfur clusters (ISCs) (Foury et al., 1999). It was shown 
that yeast carrying the YFH1 mutation was deficient in multiple ISC-dependent enzyme activities. 
ISCs are complexes of iron and sulphur atoms that serve as prosthetic groups for a series of 
enzymes with different functions, including energy metabolism (i.e. aconitase; complexes I, II, and 
III of the respiratory chain), iron metabolism (i.e. iron responsive protein I and ferrochelatase), 
purine synthesis, and DNA repair. ISC containing enzymes are localized in various cellular 
compartments, including mitochondria, cytosol, and nucleus. Rotig and co-workers (1997) found 
selective deficiencies of respiratory chain complexes I, II and III and a reduction of the cytosolic 
and mitochondrial aconitase activities in heart biopsies of FRDA patients. All the deficient enzymes 
and the complexes containing iron sulfur (Fe –S) clusters in their active sites are particularly 
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sensitive to free radicals. Deficiency restricted to Fe-S proteins has not been found in 60 biopsies of 
patients with cardiomyopathy, indicating that this inactivation is associated specifically with 
depletion of frataxin. Another hypothesis on the function of frataxin proposed by Isaya and 
collaborators (2004), is that frataxin could be a binding protein that stores iron in a bioavailable and 
non-toxic form for the synthesis of the clusters Fe -S and heme groups Furthermore, studies 
performed in cultured cells from patients with FRDA have confirmed that frataxin deficiency 
causes anomalies in sulphur amino acids, energy metabolism and mitochondrial function (Tan et al., 
2003). Also, the absence of in yeast also leads to DNA damage, as evidenced by increased nuclear 
and mitochondrial DNA damage, increased chromosomal instability including recombination and 
mutation, and greater sensitivity to DNA-damaging agents. Excess iron in the presence of oxygen 
also can generate superoxide and hydroxyl radicals, both of which are ROS. High ROS levels could 
cause damage to nuclear and mitochondrial DNA which are both radical-sensitive. (Karthikeyan et 
al.,2002). Frataxin was also reported to be necessary for the embryonic development and 
differentiation in different model organism. In the plant Arabidopsis thaliana, frataxin knock-out 
results in early embryonic lethality (Vazzola et al., 2007). Mutant atfh-1 plants with less than 50% 
of normal frataxin levels show retarded growth, without any morphological abnormalities in roots, 
leaves and flowers, and impaired fructification. Total deletion of the frataxin gene in the mouse 
resulted in embryonic lethality (Cosseè et al.,2000). Several studies suggest that frataxin has the 
role as tumor suppressor by increasing cellular oxidative metabolism and apoptotic Bax-dependent 
and p53-independent pathway (Schulz et al., 2006). 
Finally, it has been proposed that frataxin is involved in controlling oxidative stress by reducing the 
production of reactive oxygen species (ROS): Such a role could be linked easily with either the 
chaperone or the ferritin-like hypothesis, or with both. According to a ferritin-like model, the 
protein could first bind to Fe
2+
, transform it into Fe
3+
 through ferroxidase chemistry, and retain the 
bound metal in a bioavailable form (Park et al., 2003). Frataxin deficient cells have increased 
intracellular ROS levels and decreased antioxidant defenses. The exact sequence of events that 
occur in FRDA cells has not been clarified yet.  Paupe and colleagues (2009) have shown that the 
Nrf2-dependent Phase II antioxidant pathway is defective in frataxin-deficient fibroblasts. Under 
normal conditions, the activity of the transcription factor Nrf2 is regulated by the actin-associated 
Keap1 protein, which sequesters Nrf2 in the cytoplasm and promotes its degradation via 
ubiquitination. Under conditions of stress, this interaction is disrupted and Nrf2 is translocated into 
the nucleus, where it binds to DNA sequences of the cis-acting ARE (antioxidant responsive 
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element), activating the expression of Phase II antioxidant genes, including SODs, catalase, 
glutathione S-transferase and NADH quinone oxidoreductase. 
 
 
 
Fig.1.12 Schematic representation of the biological pathways altered in Friedreich’s ataxia (FRDA) as 
consequences of frataxin deficiency in mitochondria. 
 
1.6 Pharmacological Treatments and Therapeutic Strategies for 
Friedreich’s Ataxia 
No approved cure is currently available to FRDA patients. Therapeutic strategies are based on the 
use of anti-oxidants or iron chelators, with controversial results. Other strategies are in earlier 
clinical phases or pre-clinical stage. Ongoing clinical trials are illustrated (Figure 1.17). 
 
Antioxidant molecules 
Based on the studies that frataxin deficient cells are more sensitive to oxidative stress, different 
molecules with antioxidant activities were evaluated as potential therapeutic agents in FRDA. 
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Among these molecules, CoQ10 (coenzyme Q10), idebenone and mitochinone (MitoQ) 
(respectively, an analogue and a derivative of CoQ10) and vitamin E have been extensively tested 
in FRDA. Co-enzyme Q10 (2,3-dimethoxy-5-methyl-6-decaprenyl benzoquinone or ubiquinone) is 
a small lipophilic molecule present within the inner mitochondrial membrane in association with the 
electron transporter chain (ETC) complexes, which transfers electrons between complexes I and II, 
and from oxidation of fatty acids and branched chain amino acids to complex III resulting in the 
ultimate production of ATP. Structurally, it has a benzoquinone nucleus which is readily reduced to 
ubisemiquinone and ultimately to ubiquinol, as well as a 10-unit polyisoprenoid side chain 
conferring hydrophobicity (Orsucci et al. 2011; Hargreaves 2003; Lenaz et al. 2007). Because of its 
facility at undergoing redox reactions, coenzyme Q10 acts as a potent antioxidant preventing 
oxidation of proteins, lipids, lipoproteins and DNA, and maintaining other antioxidants such as 
ascorbic acid and vitamin E. It is the only endogenously synthesized lipid-soluble antioxidant. It 
also contributes to preventing the opening of the mitochondrial membrane transition pore which 
permits passage of enzymes and other molecules which can contribute to the depolarization of the 
mitochondrial membrane potential as the DNA fragmentation and apoptotic events. Co-enzyme 
Q10 may also have anti-inflammatory and anti-atherosclerotic properties (Bentinger et al. 2010). 
Clinical trials of co-enzyme Q10 were initiated treating 10 FRDA patients with 400 mg/day co-
enzyme Q10 and 2100 IU/day vitamin E for 6 months (Lodi et al. 2001). However, in this study no 
significant change was found in ICARS and in the echocardiography parameters. Likewise to Co-
enzyme Q10, the idebenone (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone) can 
act as an electron carrier within the electron transporter chain (ETC) (Suno and Nagaoka 1984). 
Results derived from a first preliminary study have demonstrated an improvement of cardiac 
function with variable neurological results secondary (Mariotti et al., 2002). Currently, FRDA 
patients regularly take idebenone, an analogue of coenzyme Q10, which exerts its beneficial effects 
by ameliorating cardiac and cerebellum function and modulating oxidative stress (Meier et al., 2009 
and Santos et al., 2010). Nevertheless, a recent research has shown that in a 6-month randomized, 
double-blind, controlled study, idebenone did not improve cardiac or neurological function (Lynch 
et al., 2010 and Lagedrost et al., 2011). For this reason, researchers are focused on development a 
new molecules with higher antioxidant, neuroprotective, and cardioprotective proprieties  
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Fig.1.13 Chemical structure of Co-Enzyme Q10 and Idebenone 
 
Further molecule which has antioxidant activity and can be considered as a possible therapeutic 
approach for the FRDA is Vitamin E. The term Vitamin E is the generic name used to denote a 
family of lipidic-soluble antioxidants, which includes two classes of compounds:  
• tocopherols (α, β, γ and δ,);  
• tocotrienols (α, β, γ and δ).  
Vitamin E is present to various extents in most edible oils, including those extracted from wheat 
germ oil, wheat, rice, bran, barley, oats, coconut and palm. (http://www.tocotrienol.org). (Aggarwal 
et al., 2010). Tocopherols consist of a chromanol ring and a 15-carbon tail. The presence of three 
trans double bonds in the tail distinguishes tocopherols from tocotrienols. The isomeric forms of 
tocotrienol are distinguished by the number and location of methyl groups on the chromanol rings: 
a-tocotrienol is 5, 7, 8-trimethyl; b-tocotrienol is 5,8-dimethyl; g-tocotrienol is 7,8-dimethyl and d-
tocotrienol is 8-monomethy. (Sen et al., 2007) 
Vitamin E acts as an antioxidant "chain breaker" able to prevent the propagation of radical 
reactions. Various studies indicate that tocotrienols exhibit antioxidant, antiproliferative, 
antisurvival, proapoptotic, antiangiogenic, and anti-inflammatory activities. The antioxidant 
proprieties of tocotrienols are mediated through induction of antioxidant enzymes such as 
superoxide dismutase, NADPH, quinone oxidoreductase and glutathione peroxidase. (Lee et 
al.,2009). Tocotrienols also have cardioprotective effects due to their antioxidant mechanisms and 
their ability to suppress inflammation, inhibit HMG-CoA reductase, a rate-limiting enzyme in 
cholesterol biosynthesis (Pearce et al., 1992 and Parker et al., 1993), and reduce the expression of 
adhesion molecules and monocyte–endothelial cell adhesion (Theriault et al., 2001). Tocopherols 
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and tocotrienols are essential for neurological function. Deficiency of this vitamin is now known to 
cause severe degenerative diseases such as Ataxia, Duchenne muscular dystrophy-like muscle 
degeneration (Aggarwal et al., 2010). Recent results have documented the neuroprotective potential 
of tocotrienols. Also, Anderson and colleagues (2003) have shown that tocotrienol is able to 
regulate directly the expression of IKBKAP whose alteration is responsible for a neurodegenerative 
disease, familial dysautonomia 
 
 
 
Fig.1.14 Chemical structure of tocotrienols and tocopherols. 
 
Finally, analogues of CoQ10 have also been developed: one of these, called MitoQ, protects the 
fibroblasts of patients from oxidative stress with endogenous high efficiency (Jauslin et al., 2003) 
while the α-tocopherol-quinone EPI-A0001, seems lead an improvement in the neurological 
function assessed by FARS scale in the preclinical phase II studies. 
 
Iron Chelators  
The use of iron chelators in FRDA was first proposed as mean to eliminate the excess iron 
accumulating in mitochondria, thus decreasing free radical generation through the Fenton reaction. 
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The possible role of iron chelation in the treatment of FRDA and other neurological diseases is still 
largely debated in literature (Richardson et al., 2001 and Kalinowsky et al., 2005). MRI studies in 
FRDA have shown that iron accumulates typically in the heart, in the dentate nucleus of the 
cerebellum while the plasma levels of iron, ferritin, and heme are generally maintained to normal 
levels (Waldvogel et al., 1999). Currently, the research is aimed at designating a molecule orally 
active and permeable to membranes, able to chelate specific areas of the brain without reducing the 
bioavailability of iron essential to eme biosynthesis. Deferiprone, an orally administered, 
lipidsoluble iron chelator used in several countries as an alternative to desferoxamine to treat iron 
overload in polytransfused individuals with hemoglobinopathies, can easily cross the blood–brain 
barrier and cellular membrane. Results derived from studies in various cells type, have shown that 
the deferiprone is able to act as a siderophore and to chelate the labile iron that is present in both 
cytosolic and mitochondrial compartments and redistribute it between all cellular compartments. 
(Sohn et al., 2008). In a pilot, open label study, the administration of deferiprone (20–30 mg/kg/day 
for 6 months) in eight of the 13 young patients FRDA enrolled, was able to reduce the iron deposits 
at the level of the dentate nucleus, after only two months of treatment (Boddaert.et al., 2007). 
However, the variegated appearance of adverse reactions observed in four patients, has imposed a 
careful and constant monitoring of hematological and biochemical parameters. In conclusion, the 
chelation of mitochondrial iron may be beneficial at an early stage of the disease, but more studies 
are necessary to monitor, in order to avoid undesirable effects. To overcome these serious side 
effects a valid alternative is the chelator Fe aroilidrazone (PCTH), resulting from another family of 
chemical molecules (compounds PCIH) which in vitro do not show the same systemic toxicity of 
deferiprone, while presenting the same ability to chelate the iron (Lim et al., 2008).  
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Fig.1.15 Mechanism of action Deferiprone 
 
Histone inhibitors deacetylase (HDACi) 
 
Histone deacetylase inhibitors (HDACi) are a new class of molecules which have been proposed for 
their ability to restore the frataxin expression and represent an innovative approach in the treatment 
of FRDA. Indeed, in FRDA the (GAA)n repeats seem to predispose the FXN gene to a series of 
epigenetic modifications that cause its silencing which appear to be caused by epigenetic 
modifications. For this reason, it has been suggested that the use of HDACi may be able to correct 
the epigenetic changes. Eighteen histone deacetylase enzymes have been identified in the human 
genome, including the zinc-dependent (class I, class II, and class IV) and the NAD+-dependent 
enzymes (class III or Sirtuins) (Gottesfeld 2013). Numerous studies have shown that small molecule 
inhibitors of the histone deacetylase (HDAC) enzymes are able to revert silent heterochromatin to 
an active chromatin conformation, and restore the normal function of genes that are silenced in 
various human diseases, including neurodegenerative and neuromotor diseases (Di Prospero et al., 
and Fischbeck et al., 2005). The efficacy of 2-aminobenzamide HDAC inhibitors 106, has been 
tested in two mouse models for FRDA (Rai et al. 2008, 2010 and Sandi et al. 2011), in which it was 
proved able to correct the deficiency of frataxin both at transcriptional and post-transcriptional 
levels, by increasing histone H3 and H4 acetylation near the GAA•TTC repeat. This study also 
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showed that the elevation of frataxin mRNA and protein was sustained, persisting 48 h after drug 
exposure in the case of the protein. There was no effect in "wild type” animals, thus indicating that 
the effect of this compound is due to removal of inhibition due to the expansion GAA (Rai et al. 
2010).  
Recently a HDAC, 109/RG2833, has completed a Phase 1 clinical trial in FRDA patients. Results 
derived from this study have shown that the treatment was well tolerated and there was an increase 
in frataxin mRNA. These results are significant in that they provide proof of principle that an 
HDAC inhibitor delivered orally (in a pill) can increase frataxin gene expression measured in blood 
from subjects (Gottesfeld 2013). An alternative therapeutic approach provides the use of 
polyamides. Polyamides are polymers which contain repeating amide, -CO-NH- linkages, able to 
interact with the unusual non B-DNA structures such a “sticky” or double/triples helix structure of 
DNA derived from the repeated sequences (GAA)n. It has been shown that Beta-alanine-linked 
pyrrole-imidazole polyamides bind GAA.TTC tracts with high affinity and disrupt the 
intramolecular DNA:DNA-associated region of the sticky-DNA conformation formed by long 
GAA.TTC repeats and restore the transcriptional repression of FXN gene (Burnett et al., 2006). 
Furthemore, Du and co-workers (2012) have demonstrated that the specific polyamide (FA1) is able 
to block the (GAA)n expansion by displacing MSH2 from FXN intron 1 in FRDA human induced 
pluripotent stem cells (iPSCs) derived from FRDA patients. 
 
 
 
Fig.1.16 Putative silencing pathway in Friedreich’s ataxia. 
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Recombinant human erythropoietin (rHuEPO) and Carbamylated erythropoietin (CEPO) 
 
Among the various therapeutic perspectives that are being considered, there are substances that 
subvert gene silencing and restore the synthesis of frataxin. An interesting therapeutic candidate in 
the treatment of FRDA is the recombinant human erythropoietin (rHuEPO). Erythropoietin (EPO) 
is a 30 400-Dalton glycoprotein that was initially recognized as a regulator of red cell production. 
EPO acts as a protective multifunctional protective molecule and exercises neuroprotective and 
cardioprotective effects (Sakanaka et al., 1998). Furthemore, EPO may attenuate the production of 
radical oxygen species (ROS) or glutamate-stimulated excitotoxicity (Calapai et al. 2000 and 
Kawakami et al. 2001). rHuEPO is a 165 amino acid glycoprotein manufactured by recombinant 
DNA technology with the same biological activities as endogenous erythropoietin and able to cross 
the blood–brain barrier (Brines et al.,2000). It was discovered that the rHuEPO increases frataxin 
expression in lymphocytes derived from FRDA patients and in primary cultures of human 
cardiomyocytes obtained from donor hearts (Sturm et al., 2005). Furthermore, in a fibroblast cell 
line from FRDA patients, rHuEPO, increases the levels of frataxin protein in the absence of 
observed changes in the expression of mRNA frataxin (Acquaviva et al., 2008). These results 
suggest a post-transcriptional regulation of frataxin by rHuEPO. Moreover, encouraging results 
have been obtained from a pilot clinical trial in which a reduction in urinary markers of oxidative 
stress such as the 8-oxo-7-hydrodeoxyguanosine (8-oxodG) and peroxides in serum after 
administration of 5000 IU rHuEPO for eight weeks, three times a week was observed. The average 
increase in frataxin observed in this trial was 27%, with a high range of variability from 15% to 
63%. Despite the commercial availability of rHuEPO as a drug with proven safety, these 
preliminary results should be interpreted with caution, as longer trials with a higher number of 
patients will be conducted where the presence of significant endpoints (Boesch et al., 2007) will be 
examined. Finally, a chemically modified EPO called Carbamylated erythropoietin (CEPO) was 
shown to stimulate the synthesis of frataxin in the lymphocytes from FRDA patients. However, a 
sponsored randomized controlled trial to evaluate secondary endpoints of the CEPO showed no 
positive results (Lundebeck.com). 
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Interferon gamma (IFNγ) 
Recently, Tomassini and co-workers (2012) have demonstrated that interferon gamma (IFNγ) can 
up-regulate the frataxin expression in different cell types, including primary cells derived from 
FRDA patients. Furthermore, in vivo IFNγ treatment is able to prevent the degeneration of DGR 
neurons of FRDA mice. The beneficial effects of IFNγ could be attributed to its ability to regulate 
the iron distribution by directly modulating the important targets of iron homeostatis as ferritin, the 
transferrin receptor (Byrd et al., 1993), the iron exporter ferroportin, its peptide ligand hepcidin 
IRP1 and the iron symporter NRAMP1 (Feelders et al., 1998 and Kim et al., 2000). 
 
Gene Therapy  
 
Fusion proteins containing the transactivator of transcription TAT, a small peptide derived from the 
human immunodeficiency virus are able to effectively deliver proteins across cell membranes and 
intracellulary (Del Gaizo et al., 2003). Recently, Piyush and colleagues (2011)have shown that a 
TAT frataxin fusion protein is correctly processed in FRDA fibroblasts and is able to bind the iron 
in free cell systems and rescue the frataxin expression by the control of “iron-oxidative” stress. The 
same study has also demonstrated that the injection of TAT–FXN protein into mice with a 
conditional loss of FXN increased their lifespan and cardiac function. Finally, the gene therapy 
through the viral vector HSV1 is still at the stage of preclinical research but can represent a curative 
treatment of the FRDA as well as for all diseases in which the alteration is found at the level of a 
gene (Gomez-Sebastian et al., 2007).  
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Fig.1.17 A schematic representation of the drugs research status in FRDA 
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Chapter II  
Oxidative Stress 
 
2.1 Radical Oxygen Species (ROS) 
Oxygen is a molecule essential for the survival of aerobic organisms, however because of its atomic 
structure that does not allow him to accept electron pairs can generate highly unstable intermediates 
known as reactive oxygen species (ROS) (Figure 2.1) (Gutteridge et al., 2000). These species are 
the result of successive reductions until the complete reduction of oxygen to H2O and can be 
divided into two categories; oxygen free radicals (i.e. superoxide anion (O2-) and hydroxyl radical 
(OH
-
) containing an unpaired electron and the non- radical species (i.e. H2O2).  
Superoxide anion 
The superoxide anion is the first free radical that is formed as an intermediate during the 
biochemical reactions of oxygen reduction. It has a negative charge and unlike other free radicals, 
has a relatively long half-life and is able to attack a large number of substrates to complete its 
orbital. The superoxide anion can be formed through different reactions: by interaction of O2 with 
electrons sometimes leak the respiratory chain when it runs at high speeds, especially in the 
transition between the redox coenzyme Q, and cytochromes, during metal-dependent oxidation of 
molecules such adrenaline, noradrenaline or even some thiol compounds, or during some specific 
enzymatic reactions such as those catalyzed by xanthine oxidase, tryptophan dioxygenase and 
indolamines dioxygenase. The inflammatory cells produce large amounts of superoxide anion as a 
defense mechanism against bacteria or potentially harmful organisms (Fuchs, 1992). Finally, the 
dismutation of superoxide anion, either spontaneously or catalyzed by superoxide dismutase (SOD), 
is the major source of hydrogen peroxide in the cell (1) 
2O2-● + 2H+ + 2e → H2O2 + O2  ………………..(1) 
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Hydrogen peroxide 
The hydrogen peroxide (H2O2) is a reactive molecule relatively stable, able to cross the membranes 
and with a rather long half-life. It is rather cytotoxic, but it is considered a weak oxidizing agent. 
The toxicity lies in the fact that it is able to give rise to hydroxyl radical via reactions catalyzed by 
metal ions (2). 
H2O2 + Fe
2+  → 3Fe 3+ + OH + -OH………………(2) 
 
Hydroxyl radical 
In the Haber-Weiss process, a molecule of superoxide and a molecule of hydrogen peroxide are 
combined to produce one molecule of oxygen, one equivalent of hydroxyl radical and a hydroxyl 
anion.  
This process is catalyzed by the ions Fe
2+
 or Cu
2+
 (3) 
O2
-● + H2O2 → O2 + OH● + OH
- 
  (3)…………..(3) 
 
In Fenton reactions, one molecule of hydrogen peroxide is converted into a hydroxyl radical and a 
hydroxyl anion with simultaneous oxidation of Fe
2+
to Fe
3+
 (4) 
H2O2 + Fe
2+
 → ● OH● + OH- + Fe3+ (4)  
 
The Fe
3+
so produced can in turn react with a superoxide radical according to the following reaction, 
regenerating Fe
3+
 which can again react with H2O2 in the Fenton reaction (5) . 
Fe3
+
+ O2 
-
 ● → Fe2+ + O…………………. (5) 
It should be specified that the iron content in the cells and in plasma is usually bound to transport, 
storage and functional proteins, and in this form is never responsive. The Fenton reaction can then 
occur only in the presence of free iron. Iron chelators can be released from the proteins subsequent 
to a decrease of pH by the accumulation of lactic acid as a result of ischemia, hemorrhage, trauma, 
and by interaction of with O
2-
 ferritin .The hydroxyl radical OH
-
 is a highly reactive molecule with 
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strong oxidizing ability and is the agent that promotes the initial phase of peroxidative processes in 
human tissues. It is able to collide with, and damage, all cellular macromolecules; proteins, nucleic 
acids, glycosaminoglycans and especially polyunsaturated fatty acids of membrane phospholipids.
 
Singlet oxygen  
Singlet oxygen (O2*) is a highly reactive form of molecular oxygen that can be harmful to living 
systems by oxidizing organic molecules. It is a derivative of the oxygen molecule in which all 
valence electrons have opposite spin. In vitro studies have showed that O2* oxidizes many organic 
molecules including membrane lipids, proteins, amino acids, nucleic acids, nucleotides, pyridine 
nucleotides, carbohydrates and thiols. O2* can be produced by exposure to ultraviolet light (320- 
380nm) or during the macrophages activation. The action of NADPH oxidase produces the 
superoxide radical anion, which spontaneously or enzymatically, dismutes to form hydrogen 
peroxide. Myeloperoxidase, or peroxidase of macrophages, then catalyze the reduction of hydrogen 
peroxide to hypochlorous acid. The hypochlorous acid and H2O2 react in turn to generated singlet 
oxygen (Powers SK et al., 2008). 
 
Fig.2.1 Reactive Oxygen Species (ROS) 
 
2.2 Physiological and Pathological Functions of ROS 
At high concentrations free radicals, radical-derived and non-radical reactive species damage all 
biological macromolecules but at moderate concentrations the ROS play a pivotal role as regulatory 
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mediators in signaling processes. In the many organisms, the ROS mediated responses provide to 
maintaining the redox homeostasis and to protect the cells against oxidative stress (Dröge 2001). 
The physiological redox signaling required the increase in ROS concentration or the decrease in 
antioxidant activities. Many organisms use the ROS-mediated signaling to regulate different 
physiological processes. For example, phagocytic cells generate singlet oxygen to enhance 
immunological responses. Similarly, the superoxide anion produced by phagocytes, performs an 
action of defense against bacterial infections, while the hydrogen peroxide as a product resulting 
from the dysfunction of the mitochondrial chain, can act as a key regulator in apoptotic mechanisms 
(Gogvadze et al., 2008). In the same fashion, various type of non- phagocytic cells (i.e. fibroblasts, 
endothelial cells, cardiac myocytes) produce superoxide and hydrogen peroxide via NADPH 
oxidase activity, to regulate intracellular signaling cascades. ROS produced by enzymes such as 
lipoxygenase (5-LOX) and cyclooxygenases (COX) are considered important mediators in 
inflammatory responses (Bonizzi et al., 200). Vascular tone, platelet adhesion and ventilation also 
are physiological process regulated by changes ROS production (Dröge 2001). Therefore, appears 
evident the dual role of ROS: on one hand these molecules are potentially harmful to the cell, on the 
other play a regulatory role in various processes. This dual function, probably due to differences in 
the production of ROS for both duration and quantity, and can be explained with the concept of 
“hormesis”, a concept that is used in toxicology to express the trend of the response of the 
biological systems in response to exposure to toxic agents. It is a dose-response curve with a bell-
shaped trend. In the case of ROS, an increase in moderate amount and of short duration of these 
molecules may activate these molecular mechanisms that lead the cell to adapt and protect it against 
subsequent stress. However, high concentrations of ROS for long periods may activate other 
signaling pathways resulting in proteolysis and cell death (Ji et al., 2006). Small levels of ROS are 
deactivated by antioxidants. In contrast, the persistence of high levels of ROS damage cell 
components, which in turn, cause the pathological manifestations (Fig.2.2). Indeed, the excessive or 
sustained increase in ROS production has been implicated in the pathogenesis of cancer, diabetes 
mellitus, atherosclerosis, neurodegenerative diseases and other pathologic conditions.  
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Fig, 2.2.Regolatory events and their dysregulation depend on the magnitude and duration of the change in 
ROS concentration. 
The chemical modifications caused by ROS can affect all macromolecules that constitute the cell; 
lipids, proteins, carbohydrates and nitrogenous bases of nucleic acids.  
Lipid peroxidation 
ROS cause lipid peroxidation (LPO), which modifies the three-dimensional structure of the lipids 
that make up cell membranes, by changing their fluidity and permeability and compromising their 
function. The process consists of a series of chain reactions in which the unsaturated fatty acids of 
membrane phospholipids are progressively transformed into lipid radicals (L-•), peroxyl radicals 
(LOO-•) and lipid peroxide (LOOH). Lipid peroxide can easily decompose into different lipid 
species such as alkoxides (LO-•), aldehydes (malondialdehyde, MDA), alkanes, lipid epoxides and 
alcohols. Similarly, the cholesterol can suffer modifications of the same type, giving rise to 
epoxides and alcohols. Following these degenerative processes, cell membranes become rigid 
losing the fluidity and function of selective permeability that distinguishes it (Spiteller, 2006). 
Protein oxidation 
The protein oxidation may determine a change in the three-dimensional structure of the molecule 
and also can change the catalytic site of an enzyme preventing the binding with the substrate . An 
example of protein oxidative modification is carbonylation, caused by oxidation of the R-groups of 
the amino acids (Davies 1987). This process is associated to the irreversible loss of function of the 
protein that is deleted in the proteasome, allowing cell survival (Dalle Donne et al., 2006).  
Nucleic Acid Damage 
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The DNA damage consists of chemical modifications of nucleotides which often give rise to 
breakage of the nucleic acid strand or errors in the replication with the introduction of mutations. 
Oxidative alterations irreversibly inhibit the processes of transcription, translation and DNA 
replication, leading to premature senescence and cell death (Harman, 1981; Schraufstatter et al., 
1988). Oxidative damage to DNA can result in breakage of the filaments (double and single), in the 
formation of DNA-DNA (or DNA-protein) cross-links, in sister chromatid exchange, and in 
modifications of the nucleotide bases. Given the close proximity to the site of ROS production, 
mitochondrial DNA is the primary target of the toxicity of ROS. In fact, an elevate occurrence of 
spontaneous mutations arise in mitochondrial DNA compared to nuclear DNA, given also the lower 
efficiency of DNA repair in this compartment (Kakkar et al., 2007). Mutations in mitochondrial 
DNA cause further superoxide production and activation of the mitochondrial apoptotic cascade 
(Ricci et al.  2008). Most likely DNA damage is mediated by the hydroxyl radical OH-. One of the 
most characteristic alterations is the addition of OH at C-8 position of an adenine or guanine. These 
modifications can be converted by oxidation into 8 - idrossiadenine or 8 – idrossiguanine, which 
can form formammidodiammino purines, able to induce the block of DNA replication (Halliwell 
2002). The 7,8-Dihydro-8-oxodeoxyguanosine (8 OXO-dG) is one of the most frequent oxidative 
products of DNA and is often used to measure oxidative damage (Tarng 2000). The 8-OXO-dG 
showed a documented mutagenic potential which is expressed in various ways, including errors or 
loss of specificity of coupling between the bases, such as GC → AT transversions and reading 
errors on adjacent bases (Cooke, 2000). Finally, this adduct is quantitatively the most present in 
biological extracellular matrices easily accessible, such as blood and urine, and in recent years 
several analytical methods have been developed that allow a sensitive and specific determination. 
Since the 8 - OXO -dG excreted in the urine is a product of oxidized DNA, it has been used as a 
potential biomarker in many environmental exposure studies (Pilger, 2006). Furthermore, it appears 
to be elevated in several neurodegenerative disorders such as Parkinson's disease, Amyotrophic 
Lateral Sclerosis (ALS), Alzheimer's disease and Autism.  
Nitrogen radicals have the same mechanism of action as oxygen radicals. NO-and ONOO- directly 
interact with DNA causing deamination reactions and cross-linking, thus increasing the mutagenesis 
or determining the formation of sugar adducts  that cause the breakage of the DNA strand (Davis, 
2001). The structural changes that affect cellular macromolecules may influence the fate of the cell. 
In fact, limited cellular damages are usually repaired by enzyme complexes capable of restoring the 
natural molecular structures as the DNA repair enzymes. However, if the cell suffers more 
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consistent damage, the normal cellular architecture is lost and the cell either accumulates breaks and 
mutations or undergoes death by necrosis or apoptosis. 
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2.3 Cellular Antioxidant Systems 
ROS are potentially harmful chemical species that can attack any molecule in our body, making 
several changes. For this reason, organisms have developed, in the course of evolution, a complex 
antioxidant defense system, consisting of a set of enzymes, vitamins and trace elements, which 
allow to neutralize ROS and to block their oxidizing activity. The antioxidants can be classified 
according to different criteria: on the basis of the origin, in endogenous and exogenous, on the basis 
of the chemical nature, in enzymatic and non-enzymatic, and finally, on the basis of the solubility, 
in fat-soluble and water-soluble. 
 
Enzymatic or primary antioxidants  
Primary antioxidants belong to the class of a wide range of enzymes able of detoxifying ROS in the 
cell through enzymatic reactions in which the reactive oxygen species lose their reactivity and are 
transformed into harmless substances for the cell. 
Superoxide dismutase 
The superoxide dismutase (SOD) is an enzyme belonging to the family of metalloproteins 
discovered in 1969 by McCord; the function is to convert the O2 ˙ˉ in O2 and H2O2 (Rahaman, 
2007) according to the following reaction of dismutation: 
2 O2.
-
 + 2 H
+
 ⇌ O2 + H2O2 
In this reaction, one molecule of O2˙ˉ oxidizes becoming oxygen and the other molecule is both 
reduced and protonated becoming H2O2. 
SOD is present in different isoforms which are identifiable on the basis of the metal ions present in 
the active site (i.e.copper, iron and manganese), the amino acid composition and distribution in 
organisms. 
The genes encoding SOD derive from two ancestral genes, one derived from the group of Mn -SOD 
and Fe -SOD spread among all aerobic organisms from bacteria to plants to humans, the other, from 
the family of Cu / Zn –SOD, which is distributed exclusively among eukaryotic organisms 
(Rahaman, 2007). 
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In humans there are three isoforms of SOD: (SOD-1, SOD-2 and SOD-3) and all have the 
characteristic of having a transition metal redox active in their catalytic site necessary to catalyze 
the dismutation reaction (Culotta VC et al.,2006). 
The different isoforms of the enzyme SOD are also characterized by the different localization; a Cu 
SOD (SOD1) distributed into the cytoplasma and in the intermembrane space, a Mn SOD (SOD), 
mainly present in the mitochondrial matrix and a Fe -SOD (SOD-3) localized in the extracellular 
space. 
 
Catalase 
 
The degradation of H2O2 takes place via two families of enzymes, catalase and glutathione 
peroxidase, present in all aerobic organisms (Izawa et al.,1996) The catalases (CAT) are 
metalloproteins with tetrameric structure containing porphyrin in the active site, whose prosthetic 
group is represented by iron; they are localized in peroxisomes of eukaryotic cells (Izawa et 
al.,1996) These enzymes have the ability to protect tissues from peroxides. The catalase catalyzes 
the dismutation of H2O2 (at high concentrations) to H2O and molecular O2 according to the 
following reaction (Valko et al., 2006): 
 
H2O2 + H2O2 → 2 H2O + O2 
 
It is thought that the above reaction occurs in two steps: 
H2O2 + Fe(III)-CAT → H2O + O=Fe(IV)-CAT 
 
H2O2 + O=Fe(IV)-CAT → H2O + Fe(III)-CAT + O2 
 
CAT have a high speed turn-over: a single molecule can convert every minute approximately 6 
million molecules of H2O2 to H2O and O2 (Rahaman.2007). 
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Fig.2.3. Antioxidants enzymatic 
 
 
Glutathione peroxidase and glutathione reductase 
 
When the levels of hydrogen peroxide are too low to activate the catalase its decomposition is 
carried out by the activation of glutathione peroxidase (Iorio et al., 2007). The enzyme is present in 
two different forms; a selenium-dependent (GPx) and a selenium-independent (glutathione-S- 
transferase (GST) enzyme. The differences between the two enzymes are due to the number of 
subunits, the catalytic mechanisms and the binding of selenium in the active site (Valko et al.,2006; 
Rahaman.2007). 
In mammals there are five different types of GPx, which differ for the cellular localization and 
tissue specificity and have the function of reducing the peroxides. 
GPx acts in association with glutathione: a molecule present at high concentrations in cells which is 
one of the most important endogenous mechanisms of detoxification by free radicals. GPx uses 
H2O2 or an organic peroxide (ROOH) as substrate and catalyzes the conversion of peroxides to 
water or alcohol through the oxidation of reduced glutathione (GSH) (Valko et al., 2006; and 
Rahaman. 2007): 
 
2GSH + H2O2 → 2H2O + GSSG 
 
2GSH + ROOH → GSSG + ROH + H2O 
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Fig.2.4 Different GPx isoenzymes 
 
In these reactions, GPx catalyzes the reduction of H2O2 to H2O and that of organic peroxides to the 
corresponding stable alcohols (ROH) using glutathione as the source of reducing equivalents. 
Furthermore GPx is a very important enzyme in preventing lipid peroxidation and then maintain the 
structure and function of biological membranes (McCord, 2000). Another enzyme involved in the 
detoxification of oxidized substrates is the Glutatione S transferase (GST) that catalyzes the 
conjugation of oxidized GSH directly to substrates which are then eliminated from the body. In 
humans and mammals seven different classes of glutathione S-transferase, belonging to a single 
family of cytosolic and soluble enzymes, have been identified and characterized. Recently, two 
other families of enzymes in the microsomal and in the mitochondrial locations have been identified 
(Hayes 2005). 
GPX1 alters the cellular content of GSSG; in order to keep the ratio GSH/GSSG constant, GSSG is 
released from the cell into the extracellular environment and degraded or converted back to GSH. 
GSH can be regenerated by de novo synthesis or by reduction of the oxidized form GSSG by 
glutathione reductase (GR). GR is a flavoprotein that converts GSSG to GSH using NADPH as a 
reducing agent. 
GSH can be synthesized de novo through two sequential reactions: the first one is ATP-dependent 
and catalyzed by γ-glutamilcisteina synthetase (γGCS), the activity of which limits the speed of 
synthesis; the second is catalyzed by glutathione synthetase (Figure 2.5). 
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Fig.2.5 Biosynthesis and Regeneration of Glutathione 
 
 
Thioredoxin (TRX) 
 
The thiol antioxidant thioredoxin (TRX) is a protein with oxidoreductase activity which is present 
in eukaryotic and in prokaryotic cells (Rahman, 2007). In its catalytic site there are two cysteine 
residues that reduce disulfide bonds (SS) of other proteins that have been the targets of the action of 
oxygen free radicals.  
In its reduced form, the TRX contains two adjacent SH groups which are converted into a disulfide 
units in the oxidized TRX when it undergoes redox reactions with multiple proteins in the following 
reaction (Valko et al., 2006) 
 
Thioredoxin (SH) 2 + protein → thioredoxin-S2-S2 + protein-(SH) 
 
TRX1 is present in the cytoplasm and is easily inducible by many types of stress (i.e. ROS, UV 
rays). 
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Non-Enzymatic or secondary antioxidants  
 
Thiols are important non-enzymatic antioxidants. Thiol groups (-SH) are essential for the protection 
of the harmful effects of ROS (Valko et al., 2006). The most important thiol antioxidant is reduced 
glutathione (GSH), a tripeptide composed of cysteine, glycine and glutamate. GSH is among the 
most effective antioxidants products at the intracellular level, besides being a substrate for GPX and 
GST enzymes. It can act directly as a free radical scavenger during the process of detoxification of 
hydrogen peroxide and lipid hydroperoxides. GSH is very abundant in the cytosol (1-11 mM), in 
the nuclei (3-15 mM) and in mitochondria (5-11 mM) and is considered the major soluble 
antioxidant in these cellular compartments (Valko et al., 2006). Antioxidant capacity of the thiol 
compounds is due to the sulfur atom which can easily facilitate the loss of a single electron. The life 
of the radical species generated in this way as radical thiol (GS-) can be significantly longer than 
many other radicals generated during oxidative stress (Valko et al., 2006). 
Another thiol antioxidant is the α-lipoic acid (ALA). It is a disulfide derivative by octanoic acid 
which can be either soluble that water-soluble. ALA is widely distributed in cell membranes and in 
the cytosol of eukaryotic and prokaryotic cells. ALA is rapidly absorbed from the diet and 
converted to its reduced form, dihydrolipoic acid (DHLA) (Valko et al., 2006). Both forms are 
potent antioxidants and exert their action as "scavengers" of free radicals and chelators of metal 
ions; they also act in the recycle of antioxidants and in the repair of proteins damaged by oxidative 
stress. Other molecules involved in the process of detoxification of free radicals are melatonin, 
carotenoids and flavonoids. Melatonin is a hormone synthesized mainly by the pineal gland and has 
many effects on a large number of pathophysiological functions. It is a strong antioxidant that can 
easily cross cell membranes and the blood-brain barrier (Reiter et al., 1997). The main function of 
melatonin is to counteract the free radicals produced during the metabolism of oxygen (Burrows et 
al., 2000). Carotenoids are a class of pigments found in plants and in different microorganisms, can 
physically remove the singlet oxygen reacting chemically to the free radicals and can eliminate 
peroxides, thus preventing damage at the level of lipophilic compartments (Rahaman 2007) 
Flavonoids are polyphenolic compounds and secondary metabolites of plants. (Valko et al., 2006). 
The flavonoids are of particular interest for their antioxidant properties and for their ability to 
chelate metals and potential role in the prevention of chronic diseases (Rahaman 2007). Flavonoids 
are extensively studied for their protective properties against oxidative stress. These compounds are 
also ideal scavengers of peroxides and are effective inhibitors of lipid peroxidation, able to chelate 
metal ions and thus to prevent the lipid breaks caused from hydrogen peroxide. However, under 
 43 
certain conditions the flavonoids can also behave as pro–oxidants, according to the number of their 
hydroxyl groups (Valko et al., 2006). 
Another non-enzymatic antioxidant is coenzyme Q, which carries out its antioxidant action in the 
mitochondrial electron transport chain. Moreover, vitamins A, E, and C are considered to be non-
enzymatic antioxidants and are taken with the diet. Vitamin E is a potent lipid-soluble antioxidant 
which in humans is present in different forms; the most active is the ' α -tocopherol (Valko et al.,  
2006). Vitamin C is a water-soluble molecule that can be present in two forms, a reduced (ascorbic 
acid) and an oxidized (dehydroascorbic acid). Vitamin C is involved in the regeneration of the non-
radical form of vitamin E, after it has reacted with a free radical. 
 
 
Fig.2.6 Summary of enzymatic and non-enzymatic antioxidant systems 
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2.4 Oxidative Stress and Biomarkers of Oxidative Stress 
 
The word oxidative stress has been introduced for the first time in 1989 by Sies to describe an 
imbalance between the production of reactive oxygen species (ROS) and antioxidant defense 
systems. In physiological conditions, the cell maintains its internal reduced state by means of 
enzymes and molecules that counteract the production of ROS. Dysfunctions of the normal redox 
state can cause toxic effects through the production of reactive chemical species that damage cell 
components including proteins, lipids and nucleic acids (Siciliano et al., 2007).  
ROS and other reactive species are constantly produced by the body through various biochemical 
processes (Uttara et al., 2009). If the generation of ROS exceeds the antioxidant capacity of the cell 
or an imbalance of detoxification mechanisms occurs, a condition of "oxidative stress" is 
established (Sompol et al., 2009). This condition has an important role in many diseases such as 
cancer, ischemia and neurodegenerative diseases (Butterfield et al., 2007), but also plays a crucial 
role during the physiological aging process (Jha et al., 2009). Recently, there has been a growing 
interest in understanding the role of oxidative stress in the pathogenesis of neurological disorders 
(Markesbery, 1996). Different tissues have different susceptibility to oxidative stress; it is now 
known that the central nervous system (CNS) is particularly vulnerable to damage by free radicals 
for several reasons that include a limited effectiveness of the antioxidant system and a high 
consumption of oxygen to produce energy. Direct analysis of ROS is extremely difficult because of 
their high reactivity and short half-life (10
-5,
 10
-6,
 10
-9
 sec for the superoxide radical, singlet oxygen 
and the hydroxyl radical, respectively) (Tarpey et al., 2004). The study of oxidative stress is based 
on methods that detecti induced alterations of proteins, lipids and DNA. Additionally, the decrease 
of the molecules with antioxidant capacity is considered an indirect marker of oxidative stress, 
although this is more susceptible to interference of the diet. 
 
Biomarkers of protein oxidation 
 
The process of oxidation of proteins involves the introduction of new functional groups that can 
alter their function and metabolism (Dean et al., 1997). Studies on the oxidative modifications of 
proteins have shown a series of irreversible changes, including fragmentation, alteration of the 
three-dimensional structure and aggregation, all resulting in a loss of function (Dean et al., 1997 and 
Davies et al., 1999). These damaged proteins are degraded by the proteasome or by lysosomes, but 
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in some cases they can form aggregates that accumulate inside or outside the cell and are insensitive 
to degradation. The amino acid residues most sensitive to oxidation are those containing aromatic 
groups or thiol, but also aliphatic residues, that following oxidation generate the carbonyl groups. 
Carbonyl groups and the products of oxidation of tyrosine are the main biomarkers of protein 
oxidation. The carbonyl groups are a generic product of oxidation of proteins and can be generated 
by direct oxidation of the amino acids (i.e. proline, arginine, lysine, and threonine) by free radicals 
or in consequence of lipoperoxidation (LPO) or glycation / glycoxidation phenomena (Stadtman et 
al., 1997 Burcham et al., 1996 , Vlassara et al.,1994). The formation of carbonyl groups on proteins 
is considered a marker of severe oxidative stress (Stadtman et al., 2003). The measurement of total 
protein carbonyls can be carried out in plasma, serum, cell lysates and purified proteins. 
Accumulation of protein carbonyls has been demonstrated in cellular aging, in ischemia/ 
reperfusion injury, chronic inflammation (Dalle-Donne et al., 2003). Protein aggregation is a 
frequent consequence of the phenomena of oxidation, and it could contribute to the formation of 
Tyr dimers; however, some authors have demonstrated that the formation of the dimer is significant 
only in the metal-proteins, in which the intermediate radical reaction is stabilized by association 
with metal ion associated (Wilks 1992). 
  
Biomarkers of lipid oxidation 
 
The membrane phospholipids and the triglycerides of low density lipoproteins (LDL) are 
particularly susceptible to radical attack. The process of lipid peroxidation (LPO) begins with the 
subtraction of a hydrogen atom from an ethylene group adjacent to a double bond of a 
polyunsaturated fatty acid (PUFA) of lipids, thus forming a radical centered on a carbon atom. By 
the rearrangement of the double bond, they forms a conjugated diene, while the molecular oxygen 
reacts with the carbon-centered radical forming a peroxyl radical, which in turn reacts with another 
PUFA forming a hydroperoxide and a new carbon-centered radical. Lipid hydroperoxides can 
further react and form cyclic peroxides, cyclic endoperoxides, aldehydes, α, β - unsaturated 
aldehydes, such as 4 -hydroxy- nonenal (4-HNE), acrolein, and malondialdehyde (MDA). One of 
the methods most frequently used to assess the degree of LPO in vivo is the quantification of MDA 
in plasma or urine and the quantification of the 4 -hydroxy- nonenal (4-HNE) which is the main 
aldehyde generated following the attack of free radicals of n-6 PUFAs (i.e. arachidonic acid , 
linoleic acid, linolenic acid). The 4-HNE reacts readily with proteins, peptides, nucleic acids and 
phospholipids to form stable adducts that involve the introduction of new carbonyl groups (Uchida, 
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2003). Adducts of lysine (HEL) are formed by the oxidation of omega 6 fatty acids such as linoleic 
acid or arachidonic acid and are considered to be early biomarkers of lipid peroxidation. Specific 
classes of compounds generated during LPO dependent to arachidonic acid are isoprostanes. 
Isoprostanes are initially formed as fatty acids esterified to phospholipids affected by radical attack, 
then are released into the circulation by the action of membrane phospholipases (Roberts et al., 
2000). In particular, the F2- isoprostanes are the most studied class as a marker of LPO (Morrow, 
2005). 
 
 
Biomarkers of DNA oxidation 
 
The attack of ROS, in particular the hydroxyl radical on nucleic acids can cause mutations of 
specific bases and even breakage of the double helix. The most used marker of oxidative damage to 
DNA is 8-hydroxy2'-deoxyguanosine (8-oxo-dG), for which competitive ELISA methods for its 
quantification in tissue extracts or biological fluids are also available (Griffiths et al. 2002 and 
Collins et al. 2004). During the process of DNA repair, the 8 - OXO -dG is free and secreted in the 
urine as single base and also included in the DNA oligomers without further modification (Lindahl 
2001). Given its stability and specificity, the concentration of 8 -oxo -dG in the urine is one of the 
most reliable markers to assess the degree of systemic oxidative stress. However, the 8-OXO-dG 
may also derive from the degradation of the deoxynucleotide dGTP. 8-OXO-dG is considered a 
partial measure of DNA damage, relative only to guanine residues and its precursors (Dizdaroglu et 
al., 2002) . 
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2.5 Role of Oxidative Stress in Friedreich’s Ataxia 
Oxidative stress caused by deficiency of frataxin plays a pivotal role in the pathogenesis of FRDA. 
However, the precise sequences of molecular events that underlie oxidative stress in FRDA are still 
debated. Studies in humans and in different eukaryotic organisms have confirmed that the frataxin 
deficiency causes an increase of oxidative stress (Schulz et al., 2000; Bulteau et al., 2007 and 
Armostrong et al., 2010). Biomarkers of oxidative stress have been detected in the urine and blood 
of FRDA patients; the levels of 8-hydroxy-2'-deoxyguanosine, a marker of oxidative DNA damage 
(Schulz et al., 2000), and of malondialdehyde, a product of lipid peroxidation (Edmond et al.,2000), 
were higher in the urine and plasma of patients compared to healthy controls. However, in other 
studies no differences were found between the levels of 8-hydroxy-2'-deoxyguanosine (Di Prospero 
et al., 2007) and of F2- isoprostanes between patients and controls (Myers et al., 2008). However, it 
has been reported that the loss of frataxin causes an impairment of cellular enzymatic anti-oxidant 
defenses, which in turn results in accumulation of ROS and oxidative stress. Indeed, in the blood of 
patients both a reduction in the levels of free glutathione (about 15 fold) and a significant increase 
of glutathione bound to hemoglobin (approximately 2-fold) were observed (Piemonte et al., 2001). 
The glutathione-dependent redox state has been studied in detail in yeast (Auchère et al., 2008). In 
yeast cells Δyfh1 mutant for the gene encoding frataxin, the concentration of total glutathione and 
the ratio GSH/GSSG were significantly reduced. Also, the GPX was more active than the wild-type. 
In contrast, there were no significant changes in the expression of genes involved in the glutathione-
dependent system between mutant cells and controls. These results suggest that the deficiency of 
frataxin in yeast leads both to a remodeling of the defense system as glutathione -dependent 
adaptation of the cells to a state of chronic oxidative stress (Auchère et al., 2008). In addition, 
Paupe and co-workers(2009) have shown that the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
is compromised in frataxin-deficient fibroblasts. Nrf2 is a transcription factor that responds to 
oxidative stress by binding to the antioxidant response element (ARE) in the promoter of genes 
coding for antioxidant enzymes. (Dassa et al.,2008). In normal conditions, the activity of the 
transcription factor Nrf-2 is regulated by the actin–associated with the protein Kelch-like ECH-
associated protein 1(Keap1), which binds NRF2 sequestering it in the cytoplasm and promoting its 
degradation via ubiquitination. Under conditions of stress, this interaction is lacking, and the 
transcription factor Nrf-2 is translocated into the nucleus, where it binds to DNA sequences of the " 
cis-acting ARE" (antioxidant-responsive element), thus activating the expression of anti -oxidants 
phase II genes such as SOD, catalase, glutathione-S-transferase and quinone oxidoreductase 
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NADH8 (Zhu et al., 2005 and Young et al., 2005). In FRDA fibroblasts treated with oligomycin 
and TBHQ (tert-butylhydroquinone), the NRF2 is unable to translocate into the nucleus, and none 
of the previously named genes is induced. The authors have shown a disorganization of actin 
filaments in fibroblasts of patients and the consequent dissociation of Keap1 and Nrf2 from actin. 
This alteration of the cytoskeleton can be explained by changes in the pools of glutathione in the 
absence of frataxin. This causes an increase in glutathionylation and alterations in the actin 
cytoskeleton dynamics, with the consequent impairment of the pathways of anti-oxidant defense by 
Nrf2 pathway. Cortopassi and co-workers (2014) through a drug discovery program that screened a 
library of clinically-approved drugs, has identified several compounds that act as Nrf2 activators 
and rescue biochemical and cellular deficits related to frataxin deficiency. 
As already said, oxidative stress due to frataxin deficiency is frequently associated with the 
accumulation of iron deposits into mitochondria (Richardson et al. 2010). Mitochondria are 
important organelles present in every cell type, but are especially important in the nervous system. 
Mitochondrial functions are essential for neuronal development and maintenance, where they 
participate in energy production, calcium homeostasis, maintenance of membrane potential, folding 
of proteins by chaperones, axonal and dendritic transport, and the release and reuse of 
neurotransmitters in the synapses. The main function of mitochondria is energy production through 
oxidative phosphorylation (OXPHOS). OXPHOS includes two steps, the electronic transport chain 
(ETC) that generates a gradient of protons, which is then used to produce ATP by oxidative 
phosphorylation. OXPHOS is the primary source of endogenous ROS, which are produced as toxic 
products of respiration (Gonzàles-Cabo and Palau, 2013). The importance of deficit in 
mitochondrial bioenergetics in FRDA is derived by the fact that the frataxin has an essential role in 
the biosynthesis of FE-S clusters which constitute the complexes of the electron transport chain.  
Therefore, in FRDA patients, the deficit of frataxin and consequently the incomplete activity of Fe-
S clusters could cause the increase of electron leakage and increase of ROS levels and oxidative 
stress. In contrast, Bayot and colleagues (2011) have proposed an alternative hypothesis concerning 
the generation of oxidative stress in the cells of FRDA patients and derived from studies in which 
the frataxin depletion was not found to be associated with decreased activity of ISC. Indeed, it has 
been shown that in different cell lines depleted of frataxin, no decrease in ISP containing enzyme 
was found (Roting et al., 1997). Based on this results, it was hypothesized that in frataxin-depleted 
cells, deficient signaling of antioxidant defences sensitizes the frataxin-free iron-sulphur clusters to 
reactive oxygen species. This hypothesis is supported by the fact that in FRDA patients there is a 
differential pathological pattern in specific organs and tissues that appears to be related to different 
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sensitivity to oxidative damage. Therefore, further studies are needed to elucidate the precise events 
that occur in the establishment of the oxidative stress in FRDA. 
 
 
Fig.2.7 Dysregulation of Antioxidant defenses in FRDA cells 
 
Fig.2.8The vicious circle hypothesis revisited in Frda 
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Chapter III 
Research Project 
Part I: Aims 
Oxidative stress appears to play a pivotal role in the pathogenetic mechanism of FRDA. For this 
reason, treatment with natural compounds with antioxidant activities may be useful to decrease the 
harmful effects due to free radicals in FRDA. The encouraging data relating to the beneficial effects 
observed in Friedreich‟s Ataxia patients treated with tocotrienol in an earlier study, has led our 
research group to investigate the potential therapeutic role of tocotrienol in counteracting the 
oxidative stress in FRDA patients. The first aim of my research project was to identify and evaluate 
a wide array of biochemical and molecular parameters related to oxidative stress in five young 
FRDA patients before and after two months of treatment with low dose of tocotrienol 
(5mg/kgbodyweight/day), and from five young healthy subjects chosen as controls. Patients were 
taking idebenone and did not discontinue it during the experimentation. We studied the following 
biochemical parameters related to oxidative stress: white blood cell gene expression of antioxidant 
enzymes (SOD-1, SOD-2, Catalase, GPX-1, GSR and GSTM-1), plasma content of GSH and 
GSSG; plasma Oxygen Radical Absorbance Capacity; plasma protein carbonyl groups; lipid 
composition of erythrocyte membranes to elucidate the molecular mechanisms underlying the 
tocotrienol antioxidant activity. These same parameters were measured following two month-
treatment with tocotrienol, in order to evaluate the variation of the oxidative stress parameters. 
Moreover, literature reports the efficacy of tocotrienol in increasing the transcription of a gene 
whose mutation leads to Familial dysautonomia, a neurodegenerative disorder (Anderson et al., 
2003). The authors reported that in vivo supplementation with tocotrienol resulted in an increase of 
both gene expression and protein IKBAP, the protein responsible for familial dysautonomia. 
Furthermore, other studies showed that FRDA patients treated with antioxidants such as coenzyme 
Q10 and vitamin E showed an increase in mRNA frataxin expression (Lodi et al., 2005). On the 
basis of these findings, the second aim of this work was to determine whether and how the 
treatment of patients with tocotrienol is able to modulate the transcription of the frataxin (FXN) 
gene. To this purpose, we evaluated the gene expression of frataxin isoform splice variants (FXN-1, 
FXN-2 and FXN-3) in blood mononuclear cells derived from patients before and after two months 
of treatment with low dose of tocotrienol and from of healthy subjects chosen as control. Moreover, 
since a small but significant increase in FXN-3 mRNA was found, we examined whether the less 
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expressed FXN-2 and FXN-3 isoforms may have a possible role in the cell; this was accomplished 
by bioinformatics means, building a 3D-model of both isoforms and carrying out a docking study 
between FXN-2 or FXN-3 and the human complex NFS1/ISCU.  
 
Part II: Aims  
 
In FRDA, the trinucleotide repeat expansion (GAA ●TTC) of FXN gene has leads to gene silencing 
by epigenetic changes However, the study of the pathogenesis of FRDA is limited by the lack of  
availability of cellular models able to reproduce the molecular and epigenetic mechanisms of gene 
silencing. Recently, in the laboratory of Professor Gottesfeld (The Scripps Research Institute, La 
Jolla, CA), it has been demonstrated that human fibroblasts derived from subjects suffering from 
neurodegenerative diseases caused by trinucleotide expansions of triplets can be reprogrammed to 
induced pluripotent stem cells (hiPSCs) by the transduction of four defined transcription factors 
(Yamanaka et al.,2007 ). hiPSCs tecnology represent a good model to study the molecular and 
epigenetic mechanisms related to instability of (GAA)n expansions (Ku et al. , 2010). For this 
purpose, the third year of my PhD project was carried out in the laboratory of Professor Gottesfeld, 
with the aim to generate hiPSCs-derived fibroblast from FRDA patients and healthy subjects. 
Furthermore, in the laboratory of Prof. Gottesfeld 298 DNA samples (obtained from Dr. David 
Lynch, of Children‟s Hospital of Philadelphia (CHOP) extracted from FRDA patients were 
analyzed by Sequenom MassARRAY platform, in order to identify single nucleotide 
polymorphisms (SNPs) non synonyms in the encoding regions of the genes for histone 
deacetylases, sirtuins, histone acetyltransferases, and other chromatin binding and modifying 
proteins, as potential secondary genetic modifiers of FRDA disease severity. From the analysis of 
various SNPs, using the Sequenom MassArray technology platform, only 5 SNPs were found to be 
polymorphic in this group of FRDA patients. Furthermore, Lynch and co-workers have used the 
DNA repository and clinical database of the Collaborative Clinical Research Network in FRDA to 
assess the effect of SNP polymorphisms on clinical features of FRDA The majority of SNPs 
assessed did not predict outcomes. In contrast, a specific amino acid changing polymorphism 
(rs352493) in Sirtuin 6 predicted FARS, with Z2 and Z3 (neurological outcome measures) scores 
with high significance This SNP changed the amino-acid Asn46 to Ser46. Therefore, the aim of my 
research project was to generate hiPSCs from fibroblasts derived from FRDA patients carrying 
heterozygous SNP (Asn46/Ser46) or omozygous for the prevalent Asn46 allele, and fibroblasts 
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derived from healthy subjects choosen as controls (Asn46/Asn6), and to study the role of Sirtuin 6 
in order to investigate the molecular mechanisms that underlie the better outcome in individuals 
harboring the SNP (Asn46/Ser46). 
 53 
Chapter IV 
Role of Oxidative Stress in the Freidreich’s Ataxia 
Materials and Methods (Part I) 
 
Patients and Healthy Subjects 
 
Five FRDA patients and five healthy volunteers were enrolled after signing an informed consent 
form. The Child Neurology and Psychiatry Unit, IRCCS Institute of Neurological Sciences of 
Bologna, Bologna, Italy, enrolled all subjects in this study. This study was approved by the Ethical 
Committee of Regional Health Service (number 1635-08092011). FRDA was diagnosed according 
to Harding 123 diagnostic criteria Patients regularly assumed idebenone (5mg/kg body weight/day, 
which was not discontinued during the study. Healthy volunteers, used as control, were age and sex 
matched with the FRDA patients; they were not affected by any neurological or psychiatric disease 
and were not under pharmacological treatment of any type nor were assuming food integrators. 
 
Tocotrienol  
Tocotrienol dose used in this study (5mg/kgbodyweight/day) was much lower than that estimated as 
no observed adverse effect level (NOEAL) in rats or humans (Osakada et al; 2004 and Khanna et al; 
2005). Neither, FRDA patients, or healthy controls noticed adverse effects due to tocotrienol 
consumption. The tocotrienol mixture was designed by Ambrosialab s.r.l. a spin-off company of the 
University of Ferrara, Italy. It is a Palm Oil (Elaeis Guineensis) phytocomplex, prepared for the 
purposes of the study, as soft gel capsule formulation and labeled as OXI-3 (internal reference name 
ALAB103). It is composed by tocotrienols and tocopherols in the enantiomerically pure natural 
form (total tocotrienol and tocopherol: 256mg/g, of which D-tocotrienol is 197 mg/g and D-
tocopherol is 59mg/g). (For details see the table 2 in the supplementary materials part I). 
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Blood sample  
Venous blood (15 ml) was collected in Na-EDTA vacutainers. One ml whole blood was set apart 
for lipidomics evaluation (see below). The remaining was centrifuged (10 min. at 1000 x g) in order 
to separate the plasma, which was frozen at -20°C in 1 ml eppendorf sterile tubes. After diluting 
(1:1) the cell suspension with sterile Phosphate Buffered Saline (PBS), mononuclear white blood 
cells were separated from red cells by Ficoll (Histopaque 1077, Sigma, St.Louis, MO) density 
gradient centrifugation. Cells were suspended in 1 ml Trizol 
®
 Reagent (Invitrogen, Milan, Italy) 
and stored at -80°C before performing the RNA separation. 
 
Urine sample  
 
Spot urine samples (10 mL) from healthy and patient subjects were collected. Proteinuria and 
creatinine determinations were carried out by laboratory techniques. The remaining urine was 
centrifuged at 1200 g for 10 min in order to remove insoluble materials. Five mL of clear urine 
were aliquoted and stored at 280uC for hexanoyl-lysine adduct (HEL) and 8-isoprostane 
evaluations. The remaining urine was filtered with 0.45 mm filter, supplemented with 0.05% 
sodium azide and stored at -80 C° for 8-hydroxy-29-deoxyguanosine (8-oxo-dG) analysis. 
 
 
GSH /GSSG ratio determination 
 
Plasmatic glutathione (GSH) and glutathione disulphide (GSSG) were determined by High-
Performance Capillary Electrophoresis using an automated Agilent 
3D
 CE Instruments (Palo Alto, 
Ca) electrophoresis system equipped with a DAD detector (operated at 200 nm) and interfaced with 
a CoolerMaster PC. Briefly, patient plasma samples were measured with transient pseudo-
isotachophoresis after deproteinization with acetonitrile. A 20 cm effective length x 75 µm 
uncoated fused silica capillary with 300 µM phosphate buffer at pH 7.4 was used for the analysis. 
The voltage for the separation was at 10 kV. Samples were introduced by pressure injection for 40 
s., so the sample length can reach 25% of the effective capillary length and the sensitivity increases 
15-20 fold. 
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Carbonyl groups Analysis  
Albumin and IgG depletion from plasma samples 
The deep frozen crude plasma samples were defrozen to 4°C. Using the commercially available ion 
exchange based Blue Albumin and IgG Depletion kit (PROTBA-1KT, Sigma-Aldrich, France), 50 
µL of crude plasma was diluted with 150 µL of equilibration buffer (kit reagent) before application 
to the column. The protocol was performed as described in the Blue Albumin and IgG Depletion 
Kit user guide. The flow-through fraction contained the albumin/IgG depleted plasma and was 
stored at -20°C until use. Protein concentration was determined by the standard Bradford method 
(Bio-Rad Laboratories, Hercules, CA). 
Derivatization of protein carbonyls and DNP immunostaining 
After plasma sample IEF, the IPG strips used for carbonylation analysis (oxyblot) were placed in 
10mL tubes and incubated in 2 N HCl with 10 mM DNPH (2,4-dinitrophenylhydrazine, Sigma-
Aldrich, France) at 25°C for 20 min. Following the incubation enabling protein-bound carbonyl 
derivatization, the marked IPG strips were washed with 6M Urea, 20% Glycerol, 1% SDS, 150mM 
Tris-HCl pH 6.8. The marked IPG strips were then prepared for the second dimension, followed by 
protein blotting to a PVDF membrane as described previously (Korolainen et al., 2007 and 
Reinheckel et al., 2000). The PVDF membranes were incubated overnight at 4°C for 
immunostaining with the primary antibody solution consisting of a 1:10,000 dilution of the anti-
DNP IgG antibody (Sigma-Aldrich, France) in the phosphate-buffered saline (PBS) containing 3% 
non-fat dry milk (Bio-Rad Laboratories). Next, the oxyblots were washed with PBS, 20% Tween 
and incubated with the goat anti-rabbit IgG/HRP conjugate (1:3000 dilution in PBS/Milk) for 1 h at 
room temperature. An enhanced chemiluminescence kit (Immobilon Western Chemiluminescent 
AP substrate, Millipore) was used for detection.  
 
Urinary 8-oxo-dG.  
 
Urinary 8-hydroxy-29-deoxyguanosine (8-oxo-dG) was measured using the HT 8-oxo-dG ELISA 
Kit (Trevigen Inc. Gaithersburg, MD, USA) according to the manufacturer‟s instructions. Briefly, 
filtered urine was diluted1:20 with a buffer provided by the kit and added to a plate prebounded 
 56 
with 8-oxo-dG. Bound and sample 8-oxo-dG competes for binding to the anti-8-oxo-dG which was 
then added to the plate; the antibody fraction captured by the immobilized 8-oxo-dG in the plate 
was then detected by means of a HRP-conjugated secondary antibody. The assay was developed 
with tetramethylbenzidine substrate (TMB) and the absorbance was measured in a microplate reader 
at 450 nm. The 8-oxo-dG concentration was expressed in ng per milligram of creatinine. 
 
Urinary 8-isoprostane 
 
Urinary 8-isoprostane (also known as 8-epi-PGF2a, 8-iso-PGF2a or 15-isoprostane F2t) was 
determined by the use of a competitive ELISA kit (Oxford Biomedical Research Inc., Oxford, MI, 
USA). As suggested by the manufacturer, urine samples are diluted 1:5 with a buffer provided in 
the kit. The 15- isoprostane F2t in the samples competes with 15- isoprostane F2t conjugated to 
horseradish peroxidase (HRP) for binding to a polyclonal antibody specific for 15-isoprostane F2t 
coated on the microplate. A substrate was added and the absorbance was measured at 450 nm in a 
microplate reader. The 15-isoprostane F2t concentration was expressed in ng per milligram of 
creatinine. 
 
Hexanoyl-lysine adducts (HEL) 
 
(HEL) concentration was measured by a competitive ELISA kit (JaICA, Fukuroi, Shizuoka, Japan) 
in unfiltered urine of healthy and FRDA patients. According to the manufacturer‟s instructions, the 
urine samples were diluted five times with PBS. Some urine samples containing proteins were 
treated with 14 mg/mL alphachymotrypsin in PBS (pH 7.4) and incubated at 37uC O.N. Samples 
were filtered using ultra filters with cut-off molecular weight 10 kDa (Amicon Ultra, Millipore, 
Cork, Ireland). The absorbance was measured at 450 nm using a microplate reader.The HEL 
concentration was expressed in nmol per milligram of creatinine (nmol/mg creatinine). 
 
Oxygen Radical Absorbance Capacity  
 
The ORAC assay was carried out on a Fluoroskan FL® ascent (Thermo Fisher Scientific, Inc. 
Waltham, MA) with fluorescent filters (excitation wavelength: 485 nm; emission filter: 538 nm) 
following a modified protocol.Briefly, in the final assay mixture (0.2 mL total volume), fluorescein 
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sodium salt (85 nM) was used as a target of free radical attack with 2,2‟-azobis(2-amidino-propane) 
dihydrochloride (AAPH) as a peroxyl radical generator. Trolox, a water-soluble analogue of 
vitamin E, was used as a standard control: a calibration curve was carried out with 10, 20, 30, 40, 50 
μM solution. The fluorescence measurements, carried out at 37 °C, were recorded at 5 min intervals 
up 30 min after the addition of AAPH. The ORAC values, calculated as difference of the areas 
under the quenching curves of fluoresceine between the blank and the sample, were expressed as 
Trolox equivalents (TE), pH = 7.4. All the experiments were performed with three replicates.  
 
Lipidomic analysis 
 
Lipidomic analysis was carried out as previously described (Viviani Alsemi et al., 2010). Briefly, 
whole blood was centrifuged to remove plasma, then erythrocytes were lysed and membranes were 
separated by centrifugation. Phospholipids were extracted according to the method of Bligh and 
Dyer. The total phospholipids fraction was treated with KOH/MeOH solution (0.5 M) for 10 min at 
room temperature, and fatty acid methyl esters were subsequently extracted with n-hexane. GC 
analysis of released fatty acids showed separation of all fatty acids and their isomers. This was 
confirmed by comparison with commercially available references and with a library of geometrical 
trans MUFA and PUFA obtained by thiyl radical-catalysed reaction of naturally occurring lipids 
(Ferreri et al., 2005). The content of individual fatty acids in erythrocyte membranes was expressed 
as percentages of the total fatty acids identified. Specifically, we correlated the percentages of the 
main saturated and unsaturated residues of membrane phospholipids together with the sums of 
saturated (SFA), monounsaturated (MUFA) and polyunsaturated (PUFA n-3 and PUFA n-6) fatty 
acid residues, and some indicative ratios (SFA/MUFA; Palmitoleic acid-C16:1/ Palmitic acid-
C16:0; Oleic acid-C18:1/ Stearic acid-C18:0). 
The Peroxidation Index (PI) was determined from the percentages of monoenoic, dienoic, trienoic, 
tetraenoic, pentaenoic and hexaenoic fatty acids according to the following formula: 
 
PI = (% Monoenoic x 0.025) + (% Dienoic x 1) + (% Trienoic x 2) + (% Tetraenoic x 4) + (% 
Pentaenoic x 6) + (% Hexaenoic x 8). 
 
The unsaturation index (UI), also known as the index of hydrogen deficiency, was calculated from 
number of double bonds per number of unsaturation of each fatty acid. It was given by equation: 
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UI = (% Monoenoic x 1) + (% Dienoic x 2) + (% Trienoic x 3) + (% Tetraenoic x 4 )  
+ (% Pentaenoic x 5) + (% Hexaenoic x 6). 
 
RNA Extraction and cDNA Synthesis 
 
Total RNA was extracted from Trizol suspension following the manufacturer‟s instructions 
(Invitrogen, Milan, Italy). RNA quality and cDNA synthesis was assessed as previously described 
Abruzzo et al; 2010. Briefly, RNA quality was measured by evaluation of 28S and 18S rRNA band 
sharpness after denaturing electrophoresis. Genomic DNA contamination was removed by digestion 
with RNase-free Deoxyribonuclease I (DNase I) (Amplification Grade DNase I, Sigma Aldrich, St. 
Louis, MO), and its absence was assessed by PCR analysis using specific primers for HSP70 
promoter (left primer: cgccatggagaccaacaccc; right primer: gcggttccctgctctctgtc). RNA purity and 
concentration were measured by spectrophotometer (Ultrospec 3000, Pharmacia Biotech, 
Cambridge, UK). Equal amounts of total RNA were reverse transcribed using the iScript cDNA 
Synthesis Kit (Bio-Rad, Hercules CA) following the manufacturer‟s instructions. The cDNA thus 
obtained was stored at 20 °C and used for PCR and qRT-PCRs.  
 
Primer FXN Isoforms Design 
  
Specific primer sequences for frataxin isoforms, for PPARG, and for two housekeeping genes, beta 
actin and GAPDH, were designed with the help of two freely available software tools Primers3 and 
Amplify. In order to discriminate between FXN-1 and FXN-2 isoforms, the primer pairs shared the 
left primer, while the right primer was designed in the precise site where the two isoforms differ 
(i.e., in the region where the FXN-2 isoform has 8 bp insertion). FXN-3 primers were designed in 
the cDNA region following nucleotide 702. Primer sequences summarized in Table 4 (see 
Supplementary Materials Part I). PCR products were subjected to both agarose gel electrophoresis 
and amelting curve analysis. Moreover, FXN-1 and FXN-2 primer specificity were evaluated by 
enzymatic digestion of PCR products obtained with semi-quantitative PCR. 
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PCR 
 
PCR analysis was performed using a Taq PCR core kit. (Qiagen, Milan, Italy) in according to 
manufacturer‟s instructions, PCR conditions were as follows: a denaturing state at 95°C for 5 min, 
40 cycles at 95°C for 50 s, 62.5°C for 50 s, 72°C for 10 min and a final stage extension at 72°C for 
10 min, PCR products were analyzed on 2.5% agarose gel stained with ethidium bromide at 
0.5mg/ml and after one h of running at 70mV.  
 
Enzymatic Digestion of FXN-1 and FXN-2 PCR Products 
 
FXN-1 and FXN-2 PCR prodcuts, 126 bp and 133 bp, respectively were digeste with BstNI 
endonuclease (New England Biolabs, Milan, Italy), taking into account that its restriction site (5‟ 
CCWGG „3 and 3‟ GGWCC „5) is found exclusively in the FXN-2 PCR product. To this purpose, 
FXN-1 and FXN-2 PCR products were incubated with 1 X NEB Buffer 2, 1mM BSA, and 1X 
BstNI in a final reaction volume of 20 𝜇l. The digestion was carried out at 60°C for 90 min. The 
digested fragments were separated by electrophoresis on 10 % polyacrylamide gel along with 
undigested samples and were visualized by ethidium bromide staining.  
 
Quantitative RT-PCR Analysis and Statistical Analysis 
 
Quantitative RT-PCR was performed in a Bio-Rad CFX96 real-time thermal cycler using the 
SsoFast EvaGreen Supermix (Bio-Rad Laboratories, Hercules, CA). The primer sequences for 
antioxidant genes and housekeeping genes (βeta Actin and GAPDH) are list in Table 3 (See 
Supplementary materials (Part I). Data were normalized to the housekeeping genes Beta-Actin and 
GAPDH. Primers were deisgn with PRIMER3 and AMPLIFY software and whenever possible, were 
designed so as to span an exon–exon junction (Sigma-Aldrich, France- Software CFX Manager 
Software (Bio-Rad Laboratories, Hercules, CA) and qbaseplus (http://www.biogazelle.com/) was 
used to date calculation. Data were analyzed with the 2−ΔΔCT method (Livak et al; 2001) taking 
into account the efficiency of the real-time PCR reaction between 95% and 105% (Pfaffl et al; 
2001) Quantitative RT-PCR evaluations were repeated at least twice. Data were evaluated by 
ANOVA test. 
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Modelling of Human FXN-2 and FXN-3 and of the Human NFS1/ISCU Complex 
 
In order to build the 3D model of the on each ligand, consisting of 126 points (XYZ) and spacing of 
0.475 ° A that allows an unconstrained roto-translation of the ligand. For each isoform, twenty five 
independent jobs were submitted by the Lamarckian genetic algorithm, with an initial population of 
150 conformations, a cut off of 27,000generations, and with rates of mutation and crossover set to 
0.02 and 0.8, respectively. The final solution was characterized by the lowest binding energy. 
 
 
Statistical analysis 
Data were evaluated by ANOVA by using ORIGIN 6.0 (Microcal Software, Inc.). Differences were 
considered to be statistically significant when 0.01<p≤0.05 and highly significant when p≤0.01. 
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Supplementary materials (Part I) 
 
Table 1.Phenotypic and genotypic features of FRDA patients  
Gender Age at time of 
study 
Age of disease  
onset  
Length GAA Repeats Total ICARS Score 
F 13 9 830 20 
M 29 16 360 37 
M 24 11 625 81 
F 18 8 621 19 
F 27 3 560 59 
 
Table 2 Composition of OXI-3 by Ambrosialab, University of Ferrara (Italy) 
TOTAL TOCOTRIENOL AND 
TOCOPHEROL 
MINIMUM 250 mg/g (25%) 
 RANGE 
 
TYPICAL VALUE 
Total D-Tocotrienol in the mix Min. 190 mg/g  
 
197.5 mg/g 
Total D-Tocoferol in the mix Min. 51 mg/g  59 mg/g 
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Table 3; Primer sequence for antioxidant and housekeeping genes studied with qRT-PCR.  
 
Unigene 
accession 
no. 
Gene Left Primer  Right Primer  Amplicon 
length (bp) 
Hs.520640 Beta Actin* TGTGGCATCCACGAAACTAC TGATCTTGATCTTCATTGTGC
T 
175 
Hs.544577 GADPH* GGCCTCCAAGGAGTAAGACC CTGTGAGGAGGGGAGATTCA 130 
Hs.530227 HSF1** CGCCATGGAGACCAACACCC GCGGTTCCCTGCTCTCTGTC 488 
Hs.443914 SOD-1 GGTGTGGCCGATGTGTCTAT CACCTTTGCCCAAGTCATCT 112 
Hs.487046 SOD-2 GGAAGCCATCAAACGTGACT CTGATTTGGACAAGCAGCAA 148 
Hs.502302 catalase GTGCAAATGCAAGCTAGTGG TCCAATCATCCGTCAAAACA 150 
Hs.76686 GPX-1 CTCTTCGAGAAGTGCGAGGT AGGCTCGATGTCAATGGTCT 240 
Hs.433951 GPX-4 AAGGAC CTGCCCCACTATTT GGTGCACGCTGGATTTTC 145 
Hs.271510 GSR CCCGATGTATCACGCAGTTA AAACCCTGCAGCATTTCATC 129 
Hs.301961 GSTM-1 TCATTACCCTTCCCTGCACT ACCAGTCAATGCTGCTCCTT 146 
Hs.527078 PGC1-alpha TTGCTGCTCTTGAAAATGGA TTACCTGCGCAAGCTTCTCT 212 
 
*Beta-Actin and GADPH genes were used as reference genes for normalization purposes. **The 
promoter of HSF1 (HSF1 heat shock transcription factor 1) was used to exclude the presence of 
genomic DNA in the RNA preparation before carrying out the reverse transcription. 
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Table 4: Primer sequence for FXN -1, FXN-2 and FXN-3 isforms and PPARG genes studied 
with qRT-PCR.  
 
Unigene Gene left Right Amplicon 
Hs.20685  FXN-1 GATGTCTCCTTTGGGAGTGG ACGCTTAGGTCCACTGGATG 126 
Hs.20685  FXN-2 GATGTCTCCTTTGGGAGTGG CGCTTAGGTCCACTACATACCTG 133 
Hs.20685  FXN-3 CCTTGCAGACAAGCCATACA CTTCGTTGCTCACTTGCTGA 275 
Hs.162646 PPARG CATAAAGTCCTTCCCGCTGA ACCTCTTTGCTCTCCTCCTG 165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 64 
Results (Part I) 
 
GSH/GSSG ratio 
 
 
Fig.1 GSH/GSSG ratio values (Mean ± SD) of plasma from normal age-matched controls and from 
FRDA patients before the two-month add-on tocotrienol supplementation; FRDA-POST, FRDA 
patients at the end of the two-month add-on tocotrienol supplementation. Star, 0.01≤p≤0.05 by 
ANOVA. 
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Carbonyl groups Analysis  
 
 
 
Fig. 2 Level of plasma protein carbonylation (nM/mg proteins).Values represent the Mean ± SD of 
percentage oxyblot spot volumes normalized to the Coomassie-stained spot volumes (%V, where 
V= integration of OD over the spot area and where % V= V single spot / V total spots) in plasma 
derived from FRDA patients before and afeter the two-month add-on tocotrienol supplementation 
and in healthy subjects .Star, 0.01≤p≤0.05; two stars, p ≤0.01 by ANOVA. 
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Lipidomics Analysis  
 
 
 
 
Fig. 3 Relevant lipidomics parameters from normal age-matched controls and from FRDA patients 
(Mean ± SD). CTR, normal age-matched controls. FRDA patients before and after the two-month 
add-on tocotrienol supplementation. Star, 0.01≤p≤0.05 by ANOVA. The content of individual fatty 
acids in erythrocyte membranes is expressed as percentages of the total fatty acids identified. 
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Urinary Oxidative Markers 
 
 
 
 
 
  
 68 
 
 
Fig.4 Analysis Urinary Oxidative Markers of urine from normal age-matched controls and from 
FRDA patients. (A) 8-hydroxy-29-deoxyguanosine (8-OXO-dG) levels measured using the HT 8-
oxo-dG ELISA Kit. The 8-oxo-dG concentration was expressed in ng/ mg of creatinine. (B) 8-
isoprostane was determined by the use of a competitive ELISA kit. 8-isoprostane concentration was 
expressed in ng per mg/ creatinine. Controls were evaluated both before (CTR) and following 
(CTR-POST) a two-month tocotrienol supplementation. FRDA patients were evaluated both before 
(FRDA-PRE-2 months) and following (FRDA-POST-2 months) a two-month add-on tocotrienol 
supplementation. Data are expressed as (Mean ± SD). Star, 0.01≤p≤0.05 by ANOVA. (C) (HEL) 
concentration was measured by a competitive ELISA kit. The concentration was expressed in 
nmoli/ mg of creatinine.  
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Oxygen Radical Absorbance Capacity (ORAC) 
 
 
Fig. 5 Oxygen Radical Absorbance Capacity (ORAC) of plasma from normal age-matched controls 
and from FRDA patients. FRDA patients were evaluated both before (FRDA-PRE-2 months) and 
following (FRDA-POST-2 months) a two-month add-on tocotrienol supplementation. Data are 
expressed as μM Trolox/L (Mean ± SD). Star, 0.01≤p≤0.05 by ANOVA. 
 
 
 
 
 
 
  
 70 
qRT-PCR Antioxidant genes expressions  
 
 
 
Fig. 6 Gene expression study by qRT-PCR of oxidative stress enzymes in leukocyte extracts of the 
five FRDA patients examined, before (FRDA, open columns) and after (FRDA-POST, light grey 
columns) two months of tocotrienol treatment. The same genes were studied also in five age-and-
sex-matched controls (CTR, dark grey columns). Data were normalized for two housekeeping genes 
and are expressed in arbitrary units as Mean ± SD. SOD-1, Superoxide Dismutase-1; SOD-2, 
Superoxide Dismutase-2; catalase; GPX-1, Glutathione Peroxidase-1; GSR, Glutathione Reductase; 
GSTM-1, Glutathione-S-Methyl-Transferase-1. Star, 0.01≤p≤0.05 by ANOVA.  
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Enzymatic digestion of FXN-1 and FXN-2 PCR products. 
 
 
Fig. 7: (A) A representative scheme of frataxin isoform cDNAs and primer sequences. Frataxin 
isoform 1 (FXN-1) and isoform 2 (FXN-2) share the left primer sequence, while the right primer 
was specific for each isoform. Frataxin isoform 3 (FXN-3) right primer sequence was designed in 
the region downstream the 702 base pair. (B) Enzymatic digestion of FXN-1 and FXN-2 PCR 
products. A representative polyacrylamide gel electrophoresis (10%) of FXN-1 and FXN-2 PCR 
products digested or undigested with BstNI restriction enzyme. Lane 1: DNA ladder; lane 2: 
undigested FXN-1 PCR product; Lane 3: BstNI digested FXN-1 PCR product; lane 4: undigested 
FXN-2 PCR product; lane 5: BstNI digested-FXN-2 PCR product. 
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PCR analysis of frataxin isoforms in a healthy subject 
 
 
 
 
 
 
 
 
Fig. 8: Semiquantitative PCR analysis of frataxin isoforms in a healthy subject. Equal amount of a 
control subject cDNA was used for FXN-1, FXN-2, and FXN-3 semiquantitative PCR analysis. PCR 
products were run in an agarose gel electrophoresis (2.5%). M: DNA ladder; NC: negative control. 
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qRT-PCR expression of frataxin isoforms 
 
Fig. 9 qRT-PCR expression of frataxin isoforms. Frataxin isoform mRNA expression was analyzed 
by qRT-PCR in five healthy subjects (Ctr) and in five FRDA patients before (white columns) and 
after (grey columns) two-month tocotrienol supplementation. Data were normalized for two 
housekeeping genes, beta-actin and GAPDH; for each gene target, the normalized expression value 
of one control subject arbitrarily chosen was set to 1, and all other gene expression data were 
reported to that sample. Data are expressed as mean of technical triplicates } SD and analyzed by 
ANOVA. Following tocotrienol supplementation, FXN-3 mRNA increased 3.49-fold in FRDA 
patients (𝑝 ≤ 0.00000000342). 
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qRT-PCR expression of PPARG 
 
 
 
 
 
Fig. 10: qRT-PCR expression of PPARG. Peroxisome proliferatora ctivated receptors-𝛾 (PPARG) 
mRNA expression was analyzed by qRT-PCR in five healthy subjects (Ctr) and in five FRDA 
patients before (white columns) and after (grey columns) two months tocotrienol supplementation. 
Data were normalized for two housekeeping genes, beta-actin and GAPDH; for each gene target,the 
normalized expression value of one control subject arbitrarily chosen was set to 1, and all other 
gene expression data were reported to that sample. Data are expressed as mean of technical 
triplicates ±SD and analyzed by ANOVA. 
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Structural comparison of human FXN-1 with FXN-2 and FXN-3. 
 
 
 
Fig. 11: Structural comparison of human FXN-1 with FXN-2 and FXN-3. Sequence and structural 
alignment of FXN-1 (1EKG, depicted in blue) with the computed 3D models of FXN-2 and FXN-3 
(colored in green and red, resp.). The secondary structure of FXN-1 is also reported along the 
structural alignment (helices: red line; beta sheets: yellow arrow). Functional residues of the anionic 
patch and residues involved in protein stability are highlighted in black and orange, respectively, 
and are conserved in all the isoforms. 
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Docking of human FXN-1, FXN-2, and FXN-3 
 
 
 
Fig. 12: Docking of human FXN-1, FXN-2, and FXN-3 on the human tetrameric NFS1/ISCU 
complex. (a) The human iron-sulfur assembly complex was modeled adopting the E. coli 
counterpart as a template (PDB code: 3LVL). The NFS1/ISCU complex includes two copies of 
ISCU (surface representation in purple) and two copies of NFS1 (surface in cyan and yellow, resp.). 
The backbone of the three frataxin isoforms is depicted in blue (FXN-1), in green (FXN-2), and in 
red (FXN-3).The three backbones overlap with a pairwise root mean square deviation (RSMD) of 
about 1.3 ˚A. (b) Important residues essential for functional interaction are conserved in all isoforms 
and highlighted in black. Relevant interactions on the complex are highlighted in orange. Basic 
residues of NFS1 involved in the interaction with the anionic patch of frataxin (R218, R219, R221, 
and R223) are colored in light green. (c) Zooming on conserved residues among human frataxins 
was experimentally proven in yeast and humans to play a critical role in the interaction with the 
ISCU complex: W155 N146 and R165 (R161 in FXN-2 and FXN-3). 
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Discussion and Conclusions  
Part I 
Data obtained in the first part of my research project are the results of a small-scale trial involving 
five young FRDA patients who were treated for two months with a low dose of tocotrienol. 
Notwithstanding the limited number of examined subjects, our results show that most oxidative 
stress parameters studied gave clear indications that FRDA patients still suffered of oxidative stress; 
despite chronic idebenone treatment. The expression of all antioxidant enzyme transcripts in FRDA 
patients circulating mononuclear cells differed from that of healthy controls, thus suggesting per se 
an unbalance in anti-oxidant defenses of FRDA patients, despite their being treated with idebenone. 
Moreover, the expression level of most antioxidant genes was consistently modified upon the two-
month tocotrienol add-on treatment, resembling that of healthy controls. Patients had an increased 
transcription of SOD-1, SOD-2 and GSR genes, which is consistent with the fact that these genes 
are known to be induced by reactive oxygen species (ROS) (Bubici et al., 2006 and Bernadt et al., 
2007) and that chronic oxidative stress in FRDA patients' fibroblasts has been shown to increase the 
level of basal SOD enzymatic activity (Paupe et al., 2009). Catalase and GPX-1 both reacting with 
peroxides had a reduced mRNA expression in FRDA patients, as already seen in FRDA fibroblasts 
(Kemp et al., 2001) We showed that, upon tocotrienol treatment, the patients‟ relative abundance of 
five out of six examined mRNAs (with the sole exception of GSTM-1) tended to resemble that of 
normal controls. We also showed that the plasmatic GSH/GSSG ratio tended to normal values 
following treatment. It should be stressed that the GSH/GSSG ratio values are considered to be a 
more feasible measure of the plasma redox capacity than the absolute amount of GSH and GSSG 
(Jones et al., 2006). Carbonyl groups (i.e. aldehyde or ketone groups) result from the oxidation of 
some amino acids (Stadtaman et al., 2000) and serve as useful markers for metal-catalyzed protein 
oxidation that occurs under conditions of oxidative stress. The evaluation of this relevant marker in 
plasma proteins leads to the same conclusions reached by examining the other parameters discussed 
above, FRDA patients were found to display clear signs of oxidative stress, which was relieved by 
tocotrienol. Moreover, we found a baseline difference in urinary HEL levels between FRDA 
patients and healthy controls. Hexanoyl-Lysine (HEL) adducts formation results from the reaction 
of linoleic or arachidonic acid hydroperoxide or of 4-hydroxy-nonenal with Lysine residues. It is an 
oxidative stress marker (Kato et al., 1999) which may be evaluated also in urine. However, no 
differences are observed in the levels of urinary markers 8-OXO-dG and Isoprostane. 
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Plasmatic ORAC (Oxygen Radical Absorbance Capacity) values clearly show that FRDA patients' 
have a reduced plasma antioxidant capacity whereas no change is apparent upon two month 
treatment only. ORAC is the only oxidation index obtained from plasma that does not change upon 
two month tocotrienol treatment, so that it may be suggested that it is not a very sensitive indicator 
of the tissue oxidative stress. The evaluation of oxidative stress has been here approached also by 
lipidomics. The analysis of lipidic profile allows to asses changes of metabolic pathways that occur 
at the expense the membrane in response to stressful cellular events. (Chatgilialoglu et al., 2008). 
Fatty acid membrane composition of erythrocytes is representative of that of relevant tissues, such 
as liver, heart and kidney (Zambonin et al., 2006) and is affected by a number of pathological 
conditions, in particular by inflammation and oxidative stress. It is worth mentioning that 
peroxidation index gives an estimation of PUFA index prone to peroxidation, whereas the 
occurrence of oxidative stress is linked to an inflammatory status which in turn is correlated with 
the arachidonic acid content. The global lipidomics approach allowed us to track the presence of 
lipid peroxidation in FRDA patients based on the combined reduction in membrane ω3 and the 
increase in stearic acid content. In fact, peroxidation of polyunsaturated fatty acids (such as ω3) 
induces a higher rate of membrane fatty acid turnover, hence an increased stearic acid content 
Noteworthy, stearic acid is associated with the induction of TNF-alpha, a mediator of inflammatory 
processes (de Lima Salgado et al., 2011). Also associated with a pro-inflammatory profile of FRDA 
patients is the increased content in arachidonic acid and the high ω6/ω3 ratio (Wall et al., 2010). 
The increased of arachidonic acid found in erythrocyte membranes from FRDA patients is 
confirmed by the increased formation of fatty acid peroxides-lysine adduct we measured. It is thus 
encouraging that two-month tocotrienol treatment led towards a decrease of both stearic and 
arachidonic acid and somehow also of the ω6/ω3 ratio; in fact it may be hypothesized that 
protracting further the anti-oxidant treatment might result into the normalization of the patients' 
lipid membrane profile. In conclusion, our data has demonstrated that tocotrienol supplementation 
is able to considerably abate oxidative stress even when administered at very low doses (5 mg/kg 
body weight/day) and for two months only; moreover, there is evidence that a longer tocotrienol 
treatment may be even more effective. Recently, was pointed out the striking similarities of the 
symptoms in vitamin E deficiency and Frataxin deficiency (Di donato et al., 2010). The remarkable 
efficacy of tocotrienol supplementation in abating oxidative stress indexes in FRDA patients 
suggests that FRDA patients are actually lacking of antioxidant power at the membrane level. 
However, due to the impaired ability of FRDA cells to cope with ROS, the association of more than 
one antioxidant may be even more effective. Future work will be addressed at the evaluation of the 
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effects of a cocktail of antioxidants, both in FRDA cell cultures and in the patients, exploiting the 
model here developed to investigate the efficacy of the approaches for oxidative stress damage 
protection. 
This encouraging results, (Marini et al., submitted) prompted us to investigate whether tocotrienol 
could modulate the expression of the different isoforms of frataxin mRNA. Here we report for the 
first time that tocotrienol induces, exclusively in FRDA patients, a significant 3.49 fold increase of 
the FXN-3 isoform mRNA. Such increase is specific, since it does not affect FXN-1 or 
FXN2.Although, we are aware that the increase in FXN-3 gene expression should be confirmed by 
an analysis of protein expression, at present, it is not possible to measure protein expression of the 
FXN-3 isoform because a specific antibody it is not available. Marmolino and co-workers showed 
that peroxisome proliferator-activated receptors- (PPARG) is involved in the up-regulation of 
mRNA and protein frataxin expression in cell lines from FRDA patients. Tocotrienols both increase 
mRNA expression of PPAR receptors , , and  and, by directly binding their LBDs, induce an 
increase of their transcriptional activities (Fang et al., 2010). PPARG gene expression was measured 
in both treated and untreated subjects in order to evaluate whether tocotrienol enhancement of FXN-
3 was mediated by an increase in PPARG expression. The high variability in PPARG expression 
among subjects did not allow a significant conclusion to be reached; however, as already pointed 
out, tocotrienol may activate PPARG transcriptional activities in a way that is independent of its 
increase (Fang et al., 2010). On the other hand, tocotrienol may promote FXN-3 mRNA expression 
through signalling pathways alternative to PPARG, as tocotrienols are able to modulate different 
targets at transcription, translation and post-translation levels (Aggarwal et al., 2010).Whether the 
tocotrienol-induced increase in FXN-3 expression is biologically relevant obviously depends on the 
ability of the FXN-3 isoform to perform its tasks. To our knowledge, no functional and structural 
studies have been carried out for the FXN-3 isoform, therefore we performed a structural analysis 
by means of bioinformatics tools. FXN-3 and FXN-1 share a 93% protein sequence identity; from 
the comparison of their sequences, the residues known to be correlated with protein function (Dhe-
Paganon et al., 2000) and with stability (Leidgens et al., 2010) were found to be well conserved in 
sequence, secondary and tertiary structures. By modeling of the iron-sulphur assembly complex 
from E. coli and computing from it the 3D structure of the human tetrameric complex, we found 
that all relevant interactions are conserved between FXN-1, FXN-2 and FXN-3), with comparable 
docking binding energy. Despite the partial or total lack of the C-terminus alpha helix, these data 
show that both FXN-2 and FXN-3 not only have an identity of structure compared to FXN-1 but 
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also have the same ability to interact with NFS1/ISCU. These bioinformatics data show for the first 
time that both FXN-2 and FXN-3 may have a biological function and can be considered a starting 
point for future studies aimed at confirming the function of both FXN-2 and FXN-3 isoforms by 
using the purified protein. In conclusions, our results demonstrate, for the first time, i) that 
tocotrienol induces in FRDA patients the up-regulation of the FXN-3 mRNA isoform; ii) that FXN-
3 and FXN-2 proteins share the same 3D structure as FXN-1 and are apparently able to complex 
with NFS1/ISCU, thus suggesting that they may play the same functions. Since basal level of FXN-
3 is very low, its 3.49 fold increase in tocotrienol-treated patients was not enough to reach frataxin 
mRNA amounts enabling normal cellular functions (Gellera et al., 2007). The mechanism by which 
tocotrienol enhances FXN-3 mRNA levels should be further investigated. In fact, it has been 
reported that SRF and TFAP2 iron-dependent transcription factors regulate frataxin expression (Li 
et al., 2010) and that tocotrienol stimulates PPARG activity dose-dependently (Fang et al., 2010). 
Therefore, we are planning to evaluate in FRDA cell lines whether higher tocotrienol concentrations 
could further enhance frataxin mRNA levels, in PPARG dependent or independent manner. Cell 
culture studies will also allow the evaluation of variations in frataxin protein levels, which is almost 
impossible to perform in mononuclear cells, which are poor frataxin producers. This will hopefully 
enable the use of tocotrienol not only as antioxidant therapy but also as inducer of frataxin 
expression. 
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Chapter V 
Generation of human induced Pluripotent  
Stem Cells (hiPSCs) from Friedreich’s Ataxia 
(FRDA) patients 
 
Materials and Methods (Part II) 
 
Cells lines  
 
Fibroblasts, human induced pluripotent stem cells (hiPSCs), neurospheres, neurons, and HEK293T 
cells were grown at 37 °C and 5% CO2. Fibroblasts were cultured with 10% FBS in minimal 
essential medium, 2 mM glutamine, 1% non-essential amino acids, 20 mM HEPES, and 1% 
antibiotic/antimycotic(Invitrogen). iPSCs were grown on-irradiated mouse embryonic fibroblasts 
(GlobalStem, Rockville, MD) in DMEM/F-12 with 20% KnockOut serum replacement, 1 mM 
glutamine, 1% nonessential amino acids, 1% antibiotic/antimycotic, 0.1 mM Beta- mercaptoethanol 
(Invitrogen), and 20 ng/ml basic FGF (Stemgent, San Diego, CA) and passaged manually every 7 or 
8 days. Neurospheres were grown in Neurobasal-A medium with 2% B-27 supplement, 1% N-2 
supplement, 2 mM glutamine, 1% antibiotic/antimycotic, 10 mM HEPES, 20 ng/ml basic FGF, and 
20 ng/ml EGF (R&D Systems). Neuronal cells were grown on matrigel in Neurobasal-A medium 
with 2% B-27 supplement, 1% N-2 supplement, 2mM glutamine, 1% antibiotic/antimycotic, and 
10mM HEPES. HEK293T cells were grown with 10% FBS in DMEM, 2 mM glutamine, 20 mM 
HEPES, 1% nonessential amino acids, and 1% antibiotic/antimycotic. 
 
Isolation of primary fibroblasts 
 
Dermal explant cultures were established from dispase-treated skin biopsies on fibronectin 
underneath a glass coverslip with fibroblast media after 5–7 days. After establishment, primary 
dermal fibroblasts were cultured as described above. Biopsies were performed under an approved 
Human Subjects Protocol. (For phenotypic and genotypic features of fibroblasts see the 
supplementary materials Part II, Table 1 and Table 2) 
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Retrovirus production 
Retroviruses were packaged via Phoenix cells and Lipofectamine (Invitrogen). The four 
reprogramming vectors (Yamanaka et al., 2007) (http://www.addgene.org) were packaged 
individually and pseudotyped with VSV-G.  
 
 
Derivation of iPSCs  
 
Donor fibroblasts were transduced daily for 3 consecutive days, and 4 to 6 days after the last 
transduction, cells were replated onto MEFs. Beginning 1 day following, cells were given ESC 
media daily. Colonies were picked between 21 and 28 days after transduction. 
 
Derivation of Neurospheres and Neural Differentiation 
 
iPSC colonies were passaged onto high-density-irradiated mouse embryonic fibroblasts (at 
60x10
3
cells/cm2) with ROCK inhibitor (10µM; Stemgent). Induction was performed with either 
LDN (0.5µg/ml; PeproTech Inc., Rocky Hill, NJ) or (5 µM; P5499, Sigma-Aldrich) and SB431542 
(10 µM; 040010, Stemgent) in ESC medium. During induction, FRDA iPSCs were maintained for 2 
weeks without passage. Subsequently, induced colonies were dissected and transferred to 
suspension culture as neurospheres in neurobasal-A medium with EGF (20 ng/ml) and basic FGF 
(20 ng/ml). Neurospheres were maintained as a suspension culture and passaged manually every 4–
5 days. Neural differentiation was performed by dissociating neurospheres with Accutase 
(Invitrogen) and replating onto matrigel-coated plates at the density of 100.000 cells. Neurons were 
maintained in Neurobasal-A medium without EGF or FGF for 7 or 8 days after replating. 
 
Characterization of Neurons  
iPSCs-neurons derived, were grown on poly-lysine coated six-well plates. Monoclonal anti-neuron-
specific class III β-tubulin (TuJ1) antibody (MMS-435P) (Covance Inc) (1:1000 dilution) was used 
as a neuronal marker. Fluorescent secondary antibody (goat-anti mouse IgG) was obtained from 
Santa Cruz Biotechnology and used at 1:1000 dilutions. Nuclei were stained with 1µg/ml DAPI for 
20 min. The images were obtained with a Leica microscope. 
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Transfection HEK293 cells with pcDNA3.1 Flag Asn46 and pcDNA3.1 Flag 
tagged Ser46  
 
HEK293T cells were seeded at a density of 0.3 x 10
6
/ml in DMEM medium without antibiotics and 
transfected with the carrier pcDNA3.1.Flag tagged fusion protein (Addegene). The Ser46 version of 
Sirt6 was derive by site directed mutagenesis by the Asn46 version available from Addgene, which 
is cloned in the FLAG-tagged mammalian expression vector pcDNA3.1 (see 
http://www.addgene.org/13817/). Both, the prevalent Sirt 6 version Asn46 or the rare Ser46 allelic 
variant are cloned as FLAG-tagged fusion proteins in HEK293 cells. The transfection was 
performed using Lipofectamine (Life Technologies) and in accordance with the instructions 
provided by the company. 
 
 
Identification of Sirt6 SNP status by PCR amplification and direct sequencing 
 
A standard PCR was performed to amplify the sequence corresponding to the Sirtuin 6. 20ng of 
DNA were used with 50µM primer SIRT6 (GAC ACA TCC AGG AAA GC) and cycled making 
use the following: denaturation at 98 ° C for 5 minutes, 98 ° C 5 seconds, annealing at 62 ° C for 15 
sec, extension at 72 ° C for 15 sec, for 40 cycles. Subsequently, the band corresponding to Sirt6 was 
separated by electrophoresis on agarose gel and extracted using Qiaquick Gel kit extraction kit 
(Qiagen) genotyping was performed by facilities Eton Bioscence (San Diego California). 
 
 
Nucleic Acid Purification 
 
Total RNA was purified with the RNeasy Plus Mini kit (QIAGEN) according to the manufacturer. 
Genomic DNA was purified by isopropanol precipitation of cell lysates prepared in total cell lysis 
buffer (100 mM Tris, 5 mM EDTA, 0.2% SDS, 0.2 M NaCl, 200 mg/mLproteinase K [pH 8]). 
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PCR and Quantitative RT-PCR 
 
For GAA●TTC triplet-repeat length conventional PCRs, Phusion polymerase (New England 
Biolabs, Ipswich, MA) was used according to the manufacturer. 20 ng of genomic DNA and 0.1µM 
primers GAA-104F and GAA-629R were used in 20µl of reactions cycled through the following 
conditions: denaturation at 98 °C for 5 s, annealing at 70 °C for 15 s, and extension at 72 °C for 90 s 
for 40 cycles with a 5-min initial denaturation and a 5-min final extension. Quantitation of PCR 
band size was performed using an inverse power function directly correlating gel migration of a 
molecular weight ladder to its known sizes. Quantitative RT-PCR analysis was done with the 
qScript One-Step SYBRGreen qRT-PCR kit (Quanta Biosciences) according to the manufacturer. 
All primers for pluripotency markers and FXN, SirT6, Beta Actin and GAPDH genes are described 
in Supplementary materials (Table 3 and Table 4, Part II). Analysis of relative qRT data was 
performed via 2−ΔΔCT method (Livak et al; 2001)  
 
 
Western Blot Analysis 
 
Whole cell extracts (in 50 mM Tris [pH 7.4], 150 mM NaCl, 10% glycerol, 0.5% Triton X-100, 
protease inhibitor; Roche) were electrophoresed in polyacrylamide gels and transferred onto 
nitrocellulose membranes. Primary antibodies were incubated overnight, and secondary antibodies 
were incubated 1 hr at room temperature. Antibody incubation was performed in 3% BSA in TBS 
containing 0.1% Tween 20. Anti-αlpha LN 13 (2765S) and anti- GAPDH (9484) antibodies were 
obtained from (Cell Signaling) and used at 1:2000 and 1:1000 dilutions, respectively. Anti-SirT6 
(2590S) and Anti-SirT6 (62739) and antibodies were obtained from Cell Signaling and abcam, 
respectively, and used at 1:250 dilutions. IRDye 680LT-conjugated goat anti-mouse IgG (H +L; 
926-68020) and IRDye 800CW-conjugated goat anti-rabbit IgG (H+L; 926-32211) secondary 
antibodies were obtained from LI-COR Bioscience and used at a dilution of 1:5000. 
 
Immunocytochemistry 
 
Cells were fixed in 4% paraformaldehyde and permeabilized with PBS 1X and 0.1% Triton X-100. 
Primary antibodies Oct4, Tra1-81, Tra1-61, SSEA4, were obtained from Millipore (MAB4305, 
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MAB4381, MAB4303, and MAB4304) and were all used at 1:50 dilution and incubated at 4 °C 
overnight. Fluorescent secondary antibodies were obtained from Santa Cruz Biotechnology (anti-
mouse Texas Red conjugate, anti-mouse FITC conjugate, anti-rat 8 Texas Red conjugate, and anti-
rat FITC conjugate). All secondary antibodies were used at 1:100 dilutions and incubated at room 
temperature for one hour followed by nuclear staining with DAPI.  
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Supplementary materials (Part II) 
 
Table 1; Phenotypic and Genotypic data of Healthy and FRDA patients  
 
 
Table 2; Phenotypic and Genotypic data of FRDA patients harboring Sirt6 Asn 46/Ser46 
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Table 3; Primer sequences of the genes studied with RT-PCR 
Gene Left Right 
Frataxin  CTG GGT GGA GAT CTA GGA ACC TTT CCC AGT CCA GTC ATAACG 
Sirtuin6 GTC TCC TGG TCA GCC AGA CTT GGC ACA TTC TTC CAC AA  
YWHAZ ACT TTT GGT ACA TTG TGG CTT CAA CCG CCA GGA CAA ACC AGT AT 
Beta Actin TGC GTG ACA TTA AGG AGA AG GTG AGG CAG CTC GTA GCT CT  
GAPDH GAG GTC AAT GAA GGG GTC AT GAG TCA ACG GAT TTG GTC GT 
 
 
 
Table 4; Primer sequences of the pluripotency genes studied with RT-PCR 
 
Gene Left Right 
OCT-4 CCT CAC TTC ACT GCA CTG TA CAG GTT TTC TT CCC TAG CT  
SOX-2 CCC AGC AGA CTT CAC ATG T CCT CCC ATT TCC CTG GTT TT 
NANOG TGA ACC TCA GTC ACA AAC AG TGG TGG TAG GAA GAG TAA AG 
REX-1 AAA GCA TCT CCT CAT TCA TGG T TGG GCT TTC AGG TTA TTT GAC T 
TERT-1 TGT GCA CCA ACA TCT ACA AG GCG TTC TTG GTC TTC AGG AT 
GDF-3 AAAA TGT TTG TGT TGC GGT CA TCT GGC ACA GGT GTC TTC AG 
FOXD3 AAG CCC AAG AAC AG C CTA GTG A GGG TCC AGG GTC CAG TAG TTC 
GAPDH  GAG TCA ACG GAT TTG GTC GT  GAG GTC AAT GAA GGG GTC AT 
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Chapter V: 
Generation of human induced Pluripotent  
Stem Cells (hiPSCs) from Friedreich’s Ataxia 
(FRDA) patients 
 
Results Part II 
 
Correlation SNPs and disease severity outcome measures  
 
 
Tab. 1 p-values for the correlation of SNPs and disease severity outcome measures derived by 
clinical database of the Collaborative Clinical Research Network in FRDA to assess the effect of 
SNP polymorphisms on clinical features of FRDA including age of onset, FARS score, 
performance measures and composites Z2 and Z3, and presence of diabetes, cardiomyopathy or 
scoliosis. Data was analyzed by assessing the ability of individual SNPs to predict phenotype in 
regression analysis of specific outcomes measures (e.g., FARS), accounting for the confounding 
effects of GAA repeat length, sex and age. The majority of SNPs assessed did not predict outcomes. 
In contrast, a specific amino acid changing polymorphism (rs352493) in SIRT6 predicted FARS, Z2 
and Z3 scores with high significance (P=0.0016;P=0.0008;P=0.0014, respectively). 
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Western Blot analysis of HEK293 Cells Sirt6 (Asn46+) and (Ser46+) 
 
 
 
 
Fig.1 Western blots results for Sirt6 (42 kDa) protein in HEK293 cells transfected with FLAG-
tagged mammalian expression vector. From left, pcDNA 3.1.pcDNA 3.1(-) is empty vector, pcDNA 
3.1 S46 expressing the rare Ser46 version and pcDNA 3.1 N46 expressing the prevalent Asn46 
version.  
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Genotyping SirT6 SNP [Asn46/Ser46] of FRDA Fibroblasts 
 
 
 
 
 
  
(A)Fibroblast FA50 
★ 
(B)Fibroblasts FA272 
★ 
(C)Fibroblasts FA71 
★ 
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Fig.2 Genotyping of fibroblasts cell lines derived from FRDA patients harboring of Sirt6 SNP (Asn 
46/Ser46. The results were obtained from all fibroblast lines by PCR amplification and direct 
sequencing to check the Sirt6 SNP status. 
 
 
 
 
 
 
 
 
 
  
(D)Fibroblasts FA78 
★ 
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Genotyping SirT6 SNP [Asn46/Ser46] of FRDA iPSCs 
 
 
 
 
 
Fig.3 Genotyping of iPSCs derived from fibroblasts FRDA patients harboring of Sirt6 SNP (Asn 
46/Ser46. The results were obtained by PCR amplification and direct sequencing confirmed the 
Sirt6 SNP (Asn46/Ser46). 
 
 
  
(E)iPSCs FA50  
★ 
(F)iPSCs FA272 
★ 
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PCR GAA●TTC repeat lenght  
 
 
Fig 4 GAA-TTC triplet-repeat expansion analysis in fibroblasts and FRDA iPSCs. From left to right 
gel analysis of PCR products from genomic DNA obtained from fibroblasts and iPSCs FRDA. 
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Characterization of FRDA iPSCs 
 
qRT PCR Real time pluripotency genes 
 
 
 
 
 
Fig.5 Analysis of pluropotency genes expression in three iPSCs lines derived from fibroblasts of 
FRDA patients harboring the Sirt6 SNP (Asn46/Ser46) (A) iPSCs FA50, iPSCs (B) and (C) iPSCs 
FA71 by quantitative real time PCR. All iPSCs cells line shows similar expression of pluripotency 
mRNAs compared to H1 hESCs. mRNA levels are normalized to GAPDH. Error bars indicate SEM 
of triplicate measurements. 
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Immunostaining pluripotency markers. 
 
 
iPSCs FA50 
 
 
Fig. 6 iPSCs FA50 Immunostaining of pluripotency markers. Phase contrast (gray); nuclear staining 
(blue); pluripotency markers staining (green) is as denoted by the colored text labels. Tra1-60 and 
Tra1-81, surface markers; SSEA-4, stage-specific embryonic antigens; Oct4, transcription factor. 
Scale bars represent 100 mm.  
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iPSCs FA272 
 
 
Fig. 7 iPSCs FA272 Immunostaining of pluripotency markers. Phase contrast (gray); nuclear 
staining (blue); pluripotency markers staining (green and red) is as denoted by the colored text 
labels. Tra1-60 and Tra1-81, surface markers; SSEA-4, stage-specific embryonic antigens; Oct4, 
transcription factor. Scale bars represent 100 mm.  
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iPSCs FA71 
 
 
 
Fig.8. iPSCs FA71 immunostaining of pluripotency markers. Phase contrast (gray); nuclear staining 
(blue); pluripotency markers staining (green and red) is as denoted by the colored text labels. Tra1-
60 and Tra1-81, surface markers; SSEA-4, stage-specific embryonic antigens; Oct4, transcription 
factor. Scale bars represent 100 mm.  
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Characterization of FA50 Neurons 
Immunostaining neuronal marker (TUJ-1) 
 
 
 
Fig. 9 Characterization of FA50 iPSCs-derived neurons from patients harboring SNP Sirt6 
(ASN46/Ser 46) with antibody against to neurons specific class III β-tubulin (βIII), TUJ-1. 
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qRT PCR Real time analysis FXN and SirT6 expression in FRDA fibroblasts 
 
 
Fig. 10 Gene expression study by qRT-PCR of frataxin (FXN) (Fig. A) and Sirtuin 6 (SirT6) (Fig. 
B) in fibroblasts control (GM08333), FRDA patients (GM04078) and in FRDA Sirt6 arboring SNP 
(Asn46/Ser 46) (FA50, FA272, FA71, FA78). Data were normalized for GAPDH housekeeping 
gene and are expressed in arbitrary units as Mean ± SD.  
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qRT PCR Real time analysis FXN and SirT6 expression in FRDA NSCs 
 
 
Fig. 11 Gene expression study by qRT-PCR of frataxin (FXN) (Fig. A) and Sirtuin 6 (SirT6) (Fig. 
B) in neural stem cell (NSCs) control (GM08333), FRDA patients (GM04078) and in FRDA 
harboring SNP SirT6 (Asn46/Ser46) (FA50, FA272). Data were normalized for GAPDH 
housekeeping gene and are expressed in arbitrary units as Mean ± SD.  
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qRT PCR Real time analysis FXN and SirT6 expression in FRDA Neurons 
 
 
Fig. 12 Gene expression study by qRT-PCR of frataxin (FXN) (Fig. A) and Sirtuin 6 (SirT6) (Fig. 
B) in neurons control (GM08333), FRDA patients (GM04078) and in FRDA harboring SNP Sirt6 
(Asn46/Ser46) (FA50, FA272). Data were normalized for GAPDH housekeeping gene and are 
expressed in arbitrary units as Mean ± SD.  
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Western Blot Analysis of Sirt6 in Fibroblasts derive from FRDA patients (I) 
 
 
Fig.13 (A). Western blot of Sirtuin 6 protein (42 kDa) and loading control GAPDH (37 kDa) in 
fibroblasts from healthy subject and FRDA patients. From Left to right: FA50(Asn46/Ser46) FRDA 
patients harboring SNP SirT6 (Asn46/Se 46), GM04078 FRDA patients (Asn46/Asn46) , GM08333 
healthy subjects (Asn46/Asn46) (B) Densiometric analysis of Sirt6 protein normalized to GAPDH. 
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Western Blot Analysis of Sirt6 in Fibroblasts derive from FRDA patients (II) 
 
 
 
 
Fig.14 (A). Western blot of Sirtuin 6 protein(42 kDa) and loading control GAPDH (37 kDa) in 
fibroblasts from healthy subjects.and FRDA patients. Left to right: GM08333 healthy subject 
(Asn46/Asn46), GM03816 FRDA patients (Asn46/Asn46), GM04078 FRDA patients 
(Asn46/Asn46), FA50 and FA272 (Asn46/Ser46) FRDA patients harboring SNP SirT6 (Asn46/Se 
46) (B) Densiometric analysis of Sirt6 protein normalized to GAPDH. 
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Western Blot Analysis Sirt6 in Neurons FRDA 
 
 
Fig. 15 (A) Western blot of Sirtuin 6 protein (42 kDa) and loading control LN13 alpha (29 kDa) in 
Neurons from healthy subjects and FRDA patients. Left to right: FA50(Asn46/Ser46) FRDA 
patients harboring SNP Sirt6 (Asn46/Se46)neurons, GM03816 FRDA patients (Asn46/Asn46) 
neurons, GM08333 control (Asn46/Asn46) neurons; (B) Densiometric analysis of Sirt6 protein in 
neurons normalized to GAPDH.  
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Discussion and Conclusions 
Part II 
Results obtained by a screening of genetic modifiers of disease severity, have highlighted the 
potential role of a specific Sirtuin, Sirt6, in FRDA pathogenesis. Individuals who harbors a single 
nucleotide polymorphism (SNP) in the gene encoding Sirt6 (Asn46/Ser46) show a better outcome 
as identified by standard neurological measures. In order to understand the molecular mechanisms 
underlying the better outcome of FRDA patients harboring of rare variantAsn46/Ser46, as first step 
we expressed both the prevalent Asn46 version of Sirt6 or the rare Ser46 version of Sirt6 proteins in 
HEK293 cells. For this purpose, we used site-directed mutagenesis to derive the Asn46 version of 
Sirt6 from the Ser46 version available from Addgene, which is cloned in the FLAG-tagged 
mammalian expression vector pcDNA3.1. Western blot analysis of protein lysates derived from 
HEK293 cells expressing (+Asn46) and expressing the rare variant (+Ser46) of Sirt6 show that the 
Ser46 version appeared to be partially degraded in these cells, compared to the Asn46 version. We 
found, also that two fibroblast cell lines derived from FRDA heterozygous for the rare variant 
(Asn46/Ser46) have a reduced amount of Sirt6 protein compared to fibroblasts from FRDA patients 
who are homozygous (Asn46/Asn46) of the prevalent variant. Subsequently, we generated the 
induced pluripotent stem cells (iPSCs) from fibroblasts of FRDA patients with the prevalent variant 
(Asn46/Asn46) and the rare variant (Asn/Ser46) of SIRT6 SNP by retroviral transduction 
(Yamanaka et al., 2007). Both fibroblasts and iPSCs cell lines were genotyped by direct sequencing 
in order to confirm the status of heterozygosity Asn46/Ser46 or the status of homozygosity 
(Asn46/Ser46). Also, the presence of trinucleotide repeats (GAA)n were verified by standard PCR. 
Furhtermore, the iPSCs were characterized using standard methods (immunostaining of 
pluripotency markers expression and expression of pluripotency genes by qRT PCR). Subsequently, 
the neurons were derived from iPSCs by induction with small molecules. In iPSCs derived-neurons 
(Asn46/Ser46), we found that, similarly to the fibroblasts, also these cells had decreased levels of 
Sirt6 compared to neurons from iPSCs (Asn46/Asn46). However, no significant differences in 
frataxin mRNA were observed between Sirt6 Asn46/Asn46 and Sirt6 Asn46/Ser 46 fibroblasts or 
iPSCs derived neurons by qRT PCR, analysis. These data suggest that the Ser46 allele affects some 
other aspect of FRDA pathology other than FXN gene expression. In conclusions, our results 
suggest that the Ser46 variant of Sirt6 is unstable and subject to rapid turnover in fibroblasts and 
neurons FRDA harboring of the rare variant (Asn46/Ser46) and provide new preliminary 
information on the role of Sirt6 in FRDA pathogenesis. Recently, some experimental studies have 
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revealed that some members belonging to the family of Sirtuin proteins have proved to be 
functional and therapeutic targets in FRDA. Indeed, Chan and colleagues have shown that the 
Nicotidammide (Vitamin B3), a generic inhibitor of Sirtuins, is able to restore the frataxin 
expression in lymphocytes derived from FRDA patients. On the other hand, Resveratrol, a 
compound known as an activator of sirtuins, is able to increase the levels of mRNA of frataxin in 
fibroblasts and lymphocytes FRDA (Li et al., 2013). Therefore, further studies are needed to 
understand the role that sirtuins have in the modulation of gene expression of Frataxin with the aim 
of identifying specific chemical modulators as potential therapeutic agents in the treatment of 
FRDA.  
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